Scientific Programme

Time	Subject	Speakers	Moderator
15:00 – 17:00	Sickle Cell Disease – Salas 10/11 – Andar Superior		Jacques Elion
15:00 – 15:25	Pathophysiology of the vaso-occlusive crisis	Nicola Conran
15:25 – 15:50	Fetal hemoglobin in SCD	Wassim El Nemer
15:50 – 16:15	SCD Management protocols	Sandra Fátima Menosi Gualandro
16:15 – 16:35	Innovative cell therapies in SCD	Vanderson Rocha
16:35 – 17:00	Discussion

Time	Subject	Speakers	Moderators
08:30 – 08:45	Welcome	Stephen D. Nimer and Silvia M. M. Magalhães	Silvia M. M. Magalhães
08:45 – 09:15	Genetic Basis of Myelodysplastic Syndromes	Coleman Lindsley	Stephen D. Nimer and Elvira Velloso
09:15 – 09:45	Immune basis of Bone Marrow Failure	Rodrigo Calado	Stephen D. Nimer and Elvira Velloso
09:45 – 10:15	Pediatric MDS	Luiz Fernando Lopes (Brazilian Registry of Pediatric MDS)	Stephen D. Nimer and Elvira Velloso
10:15 – 10:35	Case-Based Discussion – Discussion with 3 panelists and Q&A		Elvira Velloso
10:45 – 11:00	Break
11:00 – 11:30	Spliceosome Mutations and Their Impact on Disease Biology	Luca Malcovati	Stephen D. Nimer and Rodrigo Calado
11:30 – 12:00	Epigenetic Mutations and Abnormalities	Fabíola Traina	Stephen D. Nimer and Rodrigo Calado
12:00 – 12:30	Age-Related Clonal Hematopoiesis	Silvia M. M. Magalhães	Stephen D. Nimer and Rodrigo Calado
12:30 – 12:50	Case-Based Discussions – Discussion with 3 panelists and Q&A	Rodrigo Calado	Stephen D. Nimer and Rodrigo Calado
12:50 – 14:20	Pause for Lunch
14:20 – 14:40	Risk Assessment & Prognostic Models	Ronald Feitosa Pinheiro	Luca Malcovati and Irene Lorand-Metze
14:40 – 15:10	Towards a Molecular Classification of Myelodysplastic Syndromes	Coleman Lindsley	Luca Malcovati and Irene Lorand-Metze
15:10 – 15:30	Case-Based Discussions – Discussion with 3 panelists and Q&A	Irene Lorand-Metze	Luca Malcovati and Irene Lorand-Metze
15:30 – 16:00	Break
16:00 – 16:30	Treatment of Low-Risk MDS	Silvia M. M. Magalhães	Luca Malcovati and Marcelo Iastrebner
16:30 – 17:00	Treatment of High-Risk MDS	Valeria Santini	Luca Malcovati and Marcelo Iastrebner
17:00 – 17:30	Stem Cell Transplantation	Vanderson Rocha	Luca Malcovati and Marcelo Iastrebner
17:30 – 18:00	Precision Medicine Approaches to MDS	Stephen D. Nimer	Luca Malcovati and Marcelo Iastrebner
18:00 – 18:20	Case-Based Discussions – Discussion with 3 panelists and Q&A	Marcelo Iastrebner	Fernando Duarte and Marcelo Iastrebner
18:20 – 18:30	Considerações Finais

Time	Subject	Speaker	Moderators
08:30 – 18:00	Laboratory Hemotherapy Update		Alfredo Mendrone Jr., Eugênia Maria Amorim Ubiali e Nanci Salles
08:30 – 09:00	Quality management in Hemotherapy laboratories	Leonardo Scalon de Oliveira
09:00 – 10:30	Round-table: Donors and recipients immunohematology		Lilian Castilho
09:00 – 09:20	Anti-D sera selection criteria for donors and recipients RhD typing	Lilian Castilho
09:20 – 09:40	Hemolysins or agglutinins screening in blood donors?	Shirley Castilho
09:40 – 10:00	Management of difficult cases in multiple antibodies association	Carla Luana Dinardo
10:00 – 10:20	Management of difficult cases in autoimmune hemolytic anemia	Melca Barros
10:20 – 10:30	Discussion
10:30 – 11:00	Break
11:00 – 12:30	Round-table: Laboratory tests for blood-borne diseases		Alfredo Mendrone Jr
11:00 – 11:20	Internal Quality Control for Serology and Nat laboratories	Nanci Salles
11:20 – 11:40	Internal Quality Control: daily and regular analysis	Vanderleia B. Valente
11:40 – 12:00	Samples transport validation: a practical approach	Milena B. de Oliveira
12:00 – 12:20	Ministry of Health data on external quality control of molecular and serological tests	Priscila Murador
12:20 – 12:30	Discussion
12:30 – 14:00	Break
14:00 – 15:30	Round-table: Processing and quality control of blood components – Auditório 1 – Térreo		Eugênia Maria Amorim Ubiali
14:00 – 14:20	Quality in the routine of blood components production and modification	Edson Lara Moreto
14:20 – 14:40	Blood components storage management	Fernanda Azevedo
14:40 – 15:00	Implementation of pathogen inactivation in current blood bank processes and blood components	Hans Vermeij
15:00 – 15:20	Blood components quality control: sampling x reliability	Patrícia Sierra
15:20 – 15:30	Discussion
15:30 – 16:00	Break
16:00 – 16:30	Processes validation in Hemotherapy services	Ana Paula Rocha Diniz Zanelli
16:30 – 18:00	Round-table: Hemotherapy laboratories automation		Nanci Salles
16:30 – 16:50	What have we learned and improved with the serology automation	Ana Claudia de Matos Azevedo Furlanetto
16:50 – 17:10	Automation options in donors and pre-transfusion immunohematology	Vivian Scigliano
17:10 – 17:30	Automation of molecular tests for transfusion-transmitted diseases	José Eduardo Levi
17:30 – 17:50	Validation of equipment, software and interfacing systems	Nanci Salles
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
09:00 – 12:00	II Clinical Research Course (Support: CRTI) – Auditório 3 – Térreo		Ângelo Maiolino e Eduardo Magalhães Rego (Coordinators)
09:00 – 09:30	An introduction to Clinical Research	Donald Arnold
09:30 – 10:00	Entendendo a Plataforma Brasil para a Pesquisa Clínica	Eliana Martins Miranda and Nicete Romano
10:00 – 10:30	Break
10:30 – 11:00	How to write a scientific paper	Eduardo Magalhães Rego
11:00 – 11:30	The importancy of Sample Size in the Clinical trials and statistical considerations	Eliana Martins Miranda
11:30 – 12:00	Questions and Answers
12:00 – 14:00	Pause for Lunch

Time	Subject	Speaker	Moderators
14:00 – 17:30	Training of hematologist and new fields of performance		Ângelo Maiolino, Eduardo Magalhães Rego, Helio Moraes de Souza e Laura Fogliatto
14:00 – 14:30	Medical residency in hematology: where we are and where we want to go	Rodrigo Calado
14:30 – 15:00	Performance of the hematologist in the laboratory of clinical analysis	Edgar Gil Rizzatti
15:00 – 15:30	Role of the hematologist in the pharmaceutical industry	Valnei Canutti
15:30 – 16:00	Break
16:00 – 16:30	Role of hematologist in management	Rodrigo Lima
16:30 – 17:00	New areas of action in hemotherapy and cell therapy	Alfredo Mendrone Jr.
17:00 – 17:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 17:00	I Joint Symposium of Update on Hemostasis and Thrombosis ( Auditório 2 – Hall E / Térreo )		Dalton Bertolim Précoma, Dayse Maria Lourenço, Erich Vinicius de Paula, Oscar Pereira Dutra e Rossi Murilo da Silva
08:30 – 10:00	Venous thromboembolism: diagnosis, risk factors, prophylaxis
08:30 – 08:40	Opening	Rossi Murilo da Silva e Erich Vinicius de Paula
08:40 – 09:00	Association between VTE and occlusive arterial disease: what is in the literature	Fernanda Orsi
09:00 – 09:20	Risk Stratification of VTE recurrence	Daniel Dias Ribeiro
09:20 – 09:40	nflammatory response in deep vein thrombosis	Adilson Paschoa
09:40 – 10:00	Discussion
10:00 – 10:30	Break
10:30 – 12:00	Venous thromboembolism: management		Roberto Sacilotto e Dayse Maria Lourenço
10:30 – 10:50	Use of DOACs in pediatrics	Soraia Rouxinol
10:50 – 11:10	Anticoagulation during pregnancy	André Luiz Malavasi
11:10 – 11:30	Anticoagulation in thromboses in unusual sites	Marcos Areias
11:30 – 12:00	Discussion
12:00 – 13:30	Pause for Lunch
13:30 – 15:00	Antithrombotic therapy: oral anticoagulation		João Carlos de Campos Guerra e Carlos Gun
13:30 – 13:50	Oral anticoagulation in AF: management in special patients	Carlos Gun
13:50 – 14:10	Role of oral anticoagulation in atherothrombotic disorders in the age of DOACs	Antonio Eduardo Pereira Pesaro
14:10 – 14:30	Oral anticoagulation in valvular heart diseases: management in special situations	Ricardo Pavanello
14:30 – 15:00	Discussion
15:00 – 15:30	Break
15:30 – 17:00	Special situations		Daniel Dias Ribeiro e Otávio Rizzi Coelho
15:30 – 15:50	Dose variations in clinical trials with DOACs: how to translate into clinical practice?	Dayse Maria Lourenço
15:50 – 16:10	New antiplatelet drugs: impact on clinical practice	Otávio Rizzi Coelho
16:10 – 16:30	Cryptogenic stroke: investigation and management	Gisele Sampaio
16:30 – 17:00	Discussion

Time	Subject	Moderators
09:00 – 17:00	AABB & ABHH Accreditation Program Assessors’ Training	Ricardo Haddad and Ana Paula Rocha Diniz Zanelli (coordinators)
09:00 – 10:30	Presentation of AABB/ABHH Accreditation Program
10:30 – 11:00	Break
11:00 – 12:00	Continued Accreditation Program
12:00 – 13:00	Pause for Lunch
13:00 – 15:30	Accreditation Process
15:30 – 16:00	Break
16:00 – 17:00	Training Assessment

Time	Subject	Speaker	Moderators
08:30 – 10:15	IMMUNOHEMATOLOGY – Auditório 1 – Térreo		Carla Luana Dinardo e Bruno Ribeiro Cruz
08:30 – 08:50	Understanding the Rh system and its variants	Bruno Ribeiro Cruz
08:50 – 09:10	Immunohematological analysis in patients with hemoglobinopathies	Lílian Castilho
09:10 – 09:30	Autoimmune hemolytic anemia: from bench to the selection of compatible units	Melca Maria Oliveira Barros
09:30 – 09:50	Immunohematological support for patients undergone hematopoietic stem cell transplantation	Carla Luana Dinardo
09:50 – 10:15	Discussion
10:15 – 10:45	Break
10:45 – 12:30	TRANSFUSIONAL MEDICINE		Helio Moraes de Souza e Francisco Guilherme Fujita Neto
10:45 – 11:05	Red blood cells transfusion	Ana Cristina Silva Pinto
11:05 – 11:25	Platelet transfusion in oncohematology	Helio Moraes de Souza
11:25 – 11:45	Fresh frozen plasma: when and how to transfuse	Luiz de Melo Amorim Filho
11:45 – 12:05	Granulocyte transfusion: current scenario	Ricardo de Paula Battaglini
12:05 – 12:30	Discussion
08:30 – 10:15	Blood Donation – Auditório 3 – Térreo		César de Almeida Neto e Maria Angélica de Camargo Soares
08:30 – 08:50	Motivational aspects for blood donation	César de Almeida Neto
08:50 – 09:10	How to make clinical screening of blood donors more effective	Anna Bárbara de Freitas Camargo Proietti
09:10 – 09:30	Platelet donation: typed HLA and HPA donors?	Carolina Bub
09:30 – 09:50	Factors that interfere in the loyalty of blood donors	Eugênia Maria Amorim Ubiali
09:50 – 10:15	Discussion
10:15 – 10:45	Break
10:45 – 12:30	Transfusion-Transmitted Diseases		Osnei Okumoto e Eduardo Takatu
10:45 – 11:05	Zika, dengue fever and chicungunia : current scenario	José Eduardo Levi
11:05 – 11:25	Hepatitis in endemic areas	Denys Eiti Fujimoto
11:25 – 11:45	Anti-HBc positive donors: how to manage	Antonio Eduardo Benedito Silva
11:45 – 12:05	Refusal of donors for infectious agents	Ester Cerdeira Sabino
12:05 – 12:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:20	Multiple Myeloma ( Auditório 5 -Térreo )		Gracia Martinez e Danielle Leão (coordinators)
08:30 – 08:50	Molecular Updates on Multiple Myeloma	Esteban Braggio
08:50 – 09:10	Diagnostic Update	Rosane Isabel Bittencourt
09:10 – 09:30	Minimal Residual Disease	Roberto Magalhães
09:30 – 09:50	Supportive Therapy	Walter Moisés Braga
09:50 – 10:10	Anti-infectious Prophylaxis and Vaccines	Marcia Garnica
10:10 – 10:20	Discussion
10:20 – 10:45	Break
10:45 – 12:30	Non-Hodgkin's Lymphoma		Otávio Baiocchi (coordinators)
10:45 – 11:10	Primary cutaneous B-cell lymphoma	Juliana Pereira
11:10 – 11:40	Primary Cutaneous T-Cell Lymphoma	José Antonio Sanches Júnior
11:40 – 12:10	Advanced cutaneous T-cell lymphoma The Hematologist's Approach	André Neder Ramires Abdo
12:10 – 12:30	Presentation of Two Clinical Cases with Discussion	Guilherme Perini
08:30 – 10:20	AML and ALL ( Auditório 6 – Térreo )		Eduardo Magalhães Rego e Belinda Pinto Simões (coordinators)
08:30 – 08:50	AML – Treatment of AML in Brazil	Rony Schaffel
08:50 – 09:00	AML – Case 1	Wellington Fernandes da Silva Jr. ( Presenter )
09:00 – 9:15	AML – Case 1	Maria de Lourdes Chauffaille ( Debater )
09:15 – 09:30	AML – Case 2 : AML in elderly	Maria de Lourdes Chauffaille
09:30 – 09:40	ALL – Case 1	Ronald Pallota ( Presenter )
09:40 – 09:55	ALL – Case 1	Monika Conchon ( Debater )
09:55 – 10:05	ALL – Case 2	Ires Massaut ( Presenter )
10:05 – 10:20	ALL – Case 2	Felipe Magalhães Furtado ( Debater )
10:20 – 10:45	Break
10:45 – 12:25	Myeloproliferative disorders		Kátia Borgia Barbosa Pagnano e Fabíola Traina (coordinators)
10:45 – 10:55	Challenges in the differential diagnosis of Ph-Myeloproliferative disorders. Case 1: Primary myelofibrosis	Leonardo Carvalho Palma ( Presenter )
10:55 – 11:10	Challenges in the differential diagnosis of Ph-Myeloproliferative disorders. Case 1: Primary myelofibrosis	Maria de Lourdes Chauffaille ( Debater )
11:10 – 11:20	Challenges in the differential diagnosis of Ph-Myeloproliferative disorders. Case 2: Polycythemia vera	Aline dos Santos Borgo Perazzio ( Presenter )
11:20 – 11:35	Challenges in the differential diagnosis of Ph-Myeloproliferative disorders. Case 2: Polycythemia vera	Maria de Lourdes Chauffaille ( Debater )
11:35 – 11:45	Challenges in the management of CML. Case 3: Management of arterial events with tyrosine kinase inhibitors	Márcia Torresan Delamain ( Presenter )
11:45 – 12:00	Challenges in the management of CML. Case 3: Management of arterial events with tyrosine kinase inhibitors	Kátia Barbosa Borgia Pagnano ( Debater )
12:00 – 12:10	Challenges in the management of CML. Case 4 – Resistance management in CML	Monika Conchon ( Presenter )
12:10 – 12:25	Challenges in the management of CML. Case 4 – Resistance management in CML	Vaneuza Araújo Moreira Funke ( Debater )

Time	Subject	Speaker	Moderators
08:30 – 10:50	Part I Clinical-laboratory discussion session (7/8/9 Piso Superior)		Mihoko Yamamoto e Silvia Inês Pires Ferreira
08:30 – 08:45	Leukemia cutis	Lúcia Monteiro de Castro Lima Netto
08:45 – 08:50	Discussion
08:50 – 09:05	Monoclonal T-cell lymphocytosis	Matheus Vescovi Gonçalves
09:05 – 09:10	Discussion
09:10 – 09:25	PNET versus Acute megakaryoblastic leukemia	Rodrigo Barroso
09:25 – 09:30	Discussion
09:30 – 09:45	Immunophenotypic aspects in the Parvovirus B19 infection	Alex Freire Sandes
09:45 – 09:50	Discussion
09:50 – 10:05	MM + MDS	Irene Lorand-Metze
10:05 – 10:10	Discussion
10:10 – 10:25	Early T + ALL B	Herbert Santos
10:25 – 10:30	Discussion
10:30 – 10:45	Lymphoproliferative disorder of NK-	Ana Paula Azambuja
10:45 – 10:50	Discussion
10:45 – 10:50	Break
11:05 – 12:30	Parte II – Avanços diagnósticos em Citometria de Fluxo (7/8/9 Piso Superior)		Mariester Malvezzi e Rodolfo Patussi Correia
11:05 – 11:30	O papel da técnica de Flow-FISH na avaliação de anemia aplástica	Felipe Magalhães Furtado
11:30 – 11:55	Linfocitose B monoclonal	Mariane Faria Moss
11:55 – 12:20	Cross match por citometria de fluxo	Margareth Afonso Torres
12:20 – 12:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 12:30	How to make good use of the Hematology lab in…		Kleber Fertrin e Cristina Bortolheiro
08:30 – 09:10	Neutropenia	Kleber Fertrin
09:10 – 09:20	Discussion
09:20 – 10:00	Red cell fragmentation syndromes	Cristina Bortolheiro
10:00 – 10:10	Discussion
10:10 – 10:45	Break
10:45 – 11:25	Hyperferritinemia	Kleber Fertrin
11:25 – 11:35	Discussion
11:35 – 12:20	Bone marrow infiltration	Lígia Niero-Melo
12:20 – 12:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Applications of next generation sequencing in the management of patients with acute leukemia (Salas 4/5 – Mezanino)		Luiz Gonzaga Tone, Carlos Alberto Scrideli e Paulo V. Campregher (coordenador)
08:30 – 09:00	Next-generation DNA sequencing in acute leukemias: genome, exoma and multigene panels Paulo V. Campregher	Paulo V. Campregher
09:00 – 09:30	The clinician and Foundation One: when to indicate? Israel Bendit	Israel Bendit
09:30 – 10:00	Use in clinical practice: Case Discussion	Magda Carneiro
10:00 – 10:30	Break
10:30 – 12:15	Infant Leukemias and Immunophenotyping: Controversial Diagnoses (Salas 4/5 – Mezanino)		Anita Frisanco, Ana Claudia Carramaschi Villela Soares e Maura Ikoma(coordenadora)
10:30 – 10:50	Leucemias Agudas de Linhagem Ambígua	Maura Ikoma
10:50 – 11:05	CASO CLÍNICO 1	Ana Vírginia Lopes de Souza
11:05 – 11:25	Conflicts in the Diagnosis of Mature B-cell Leukemias	Anita Frisanco
11:25 – 11:40	CASO CLÍNICO 2	Bianca Faustini
11:40 – 12:00	Myeloid Proliferations of Down Syndrome Patient.	Ana Claudia Carramaschi Villela Soares
12:00 – 12:15	CASO CLÍNICO 3	Gabriele Zamperlini Netto
08:30 – 10:00	Rare diseases: are we diagnosing and treating?		Josefina Aparecida Pellegrini Braga e Sandra Regina Loggetto
08:30 – 08:55	Exome in hematology: what to look for and how to interpret the outcome?	João Bosco de Oliveira Filho
08:55 – 09:20	Gaucher Disease	Ana Maria Martins
09:20 – 09:45	Cytopenias and immunodeficiencies	Mayra Dorna
09:45 – 10:00	Discussion
10:00 – 10:30	Break
10:30 – 12:30	Clinical Cases Management(Salas 10/11 – Mezanino)		Jaqueline Peres e Patrícia Moura
10:30 – 11:00	Exome in hematology: what to look for and how to interpret the outcome?.	João Bosco de Oliveira Filho
11:00 – 11:10	Discussion	Ana Vírginia Lopes de Souza
11:10 – 11:40	Gaucher Disease	Ana Maria Martins
11:40 – 11:50	Discussion
11:50 – 12:20	Cytopenias and immunodeficiencies	Mayra Dorna
12:20 – 12:30	Discussion

Time	Subject	Speaker	Moderator
08:30 – 10:00	Nutritional Anemias ( Auditório 4 – Hall E / Térreo )		Paulo Augusto Silveira
08:30 – 09:00	nvestigation of iron deficiency due to gastrointestinal bleeding: from clinical history to endoscopic capsule	Rodolfo Delfini Cançado
09:00 – 09:30	Oral iron treatment: once a day, twice a day or every two days?	Rodolfo Delfini Cançado
09:30 – 10:00	Vitamin B12 Deficiency: IM vs. Sublingual	Maria Stella Figueiredo
10:15 – 10:45	Discussion
10:45 – 12:30	Autoimmunity ( Auditório 4 – Hall E / Térreo )		Rodolfo Delfini Cançado
10:45 – 11:15	Autoimmune Neutropenia	José Orlando Bordin
11:15 – 11:45	Investigation on Coombs-Negative Autoimmune Hemolytic Anemia	Melca Maria Oliveira Barros
11:45 – 12:15	Treatment of anemias by cryoagglutinins	Paulo Augusto Silveira
12:15 – 12:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:15	Educational course: THROMBOSIS ( Auditório 2 – Hall E / Térreo )		Daniel Dias Ribeiro e Erich Vinicius de Paula
08:30 – 09:00	Risk Assessment and venous thromboembolism recurrence	Daniel Dias Ribeiro
09:00 – 09:30	Update on the antiphospholipid syndrome management	Fernanda Orsi
09:30 – 10:00	Venous thromboembolism management in pediatric patients	Jorge David Aivazoglou Carneiro
10:15 – 10:15	Discussion
10:15 – 10:45	Break
10:45 – 12:30	EDUCATIONAL COURSE: THROMBOCYTOPENIAS ( Auditório 2 – Hall E / Térreo )		Ana Clara Kneese Virgílio do Nascimento e Dayse Maria Lourenço
10:45 – 11:15	Update on the management of ITP	Donald M Arnold
11:15 – 11:45	Update on the management of TTP	Luciana Côrrea de Oliveira
11:45 – 12:15	Update on the management of HIT	Erica Okazaki
12:15 – 12:30	Discussion

Time	Subject	Speaker	Moderators
08:30 – 17:00	12nd Symposium on Hemotherapy Units Symposium		Ricardo Haddad (coordenador)
08:30 – 09:15	Conference: Regulation of blood products for non-transfusion purposes	João Batista da Silva Jr.	Osnei Okumoto (coordenador)
09:15 – 09:30	Discussion
09:30 – 10:15	Conference: Compliance: Dilemmas and Solutions	Barbara Lespinassi Sampaio	Ana Paula Rocha Diniz Zanelli (coordenadora)
10:15 – 10:30	Discussion
10:30 – 11:15	Conference: Financial Tools for Cash Management	Diego de Toledo	André Langhi (coordenador)
11:15 – 11:30	Discussion
11:30 – 12:15	Conference: 8 Key trends in Human Resources	José Eduardo Fernandes	Ricardo Haddad (coordenador)
12:15 – 12:30	Discussion
12:30 – 14:00	Break
14:00 – 14:45	Conference: Value-Based Health Care: Perceptions of value in the different health ecosystems of Brazil	André Ballalai Ferraz	Ana Paula Rocha Diniz Zanelli(coordenadora)
14:45 – 15:00	Discussion
15:00 – 15:45	Conference: Traceability in the processing and distribution of blood components	Edson Lara Moretto	Ricardo Haddad ( Coordenador )
15:45 – 16:00	Discussion
16:00 – 16:45	Round-table: Regulation of products of cell therapies – Challenges and Paths	João Batista da Silva Jr.	Osnei Okumoto(coordenador)
16:45 – 17:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 08:45	Opening		Marcela Ganzella Sisdelli e Thays Vieira Cusato (Coordinators )
08:45 – 10:30	Round-table: Transfusion Reaction	Marcela Ganzella Sisdelli e Thays Vieira Cusato	Elaine Negri
08:45 – 09:05	Immediate transfusion reactions	Fabrício Biscaro Pereira
09:05 – 09:25	Delayed Transfusion reactions	Fabrício Biscaro Pereira
09:25 – 09:45	Transfusions monitoring and assistance to transfusion reactions – the nurse's gaze	Marcela Ganzella Sisdelli
09:45 – 10:15	Notification of transfusion reactions on NOTIVISA	Andressa Honorato M. de Amorim
10:15 – 10:30	Discussion
10:30 – 11:00	Break
11:00 – 13:00	Round-table: Whole blood and blood components apheresis donation		Thays Vieira Cusato
11:00 – 11:25	Peripheral puncture of the external jugular for collection of peripheral blood hematopoietic progenitor cells	Nixon Ramos da Silva
11:25 – 11:50	Apheresis blood components collection: Responsibilities of the nurse	Emerson Clayton Amaro
11:50 – 12:15	Adverse reactions to whole blood donation and apheresis – FORMSUS	Andressa Honorato M. de Amorim
12:15 – 12:40	The culture of voluntary blood donation among the population	Luiza Lucia de Oliveira Silva
12:40 – 13:00	Discussion
13:00 – 14:15	Pause for Lunch
14:15 – 16:00	Round-table: Coagulopathies and Hemophilia		Ana Claudia Acerbi
14:15 – 14:45	Hemophilia: Caring for the patient with an inhibitor	Andrea Luisa de Almeida Sambo
14:45 – 15:15	Radiosynoviorthesis in hemophilia	Luciana Côrrea de Oliveira
15:15 – 15:45	Webcoagulopathies: benefits and difficulties with the system	Luciene Figueiredo
15:45 – 16:00	Use of new oral anticoagulants: guidelines and precautions	Luciana Côrrea de Oliveira
16:00 – 16:15	Break
16:15 – 17:00	Apresentação dos trabalhos orais
16:15 – 16:25	Exposição ocupacional a agrotóxicos e o câncer: uma questão de saúde pública	Ciência CTDNS, Ferreira DLM, Junior OR, Lanza MVC ( Autores )
16:25 – 16:35	Hemoterapia: A importância de conhecimentos teórico/práticos em equipes multidisciplinares dentro do ambiente hospitalar	Inácio JC, Teixeira PMN ( Autores )
16:35 – 16:45	Um estudo de caso: O Processo de Enfermagem e a Leucemia Mieloide Aguda	N RA, Roberta C, Bruna P ( Autores )
16:45 – 16:55	Vivências de adolescentes com câncer sobre a hospitalização e os cuidados de enfermagem.	Silva KMH, Silva MA, Guimarães TMR ( Autores )

Horário	Tema	Palestrante	Moderador
12:45 – 13:45	Presentation of awarded works – Auditório 5 – Hall E / Térreo		Roberto Passetto Falcão e Sara Teresinha Olalla Saad
12:45 – 12:55	Melhor trabalho em transplante de medula óssea e células tronco – SOBREVIDA PÓS TCTH EM PACIENTES ADULTOS PORTADORES DE LEUCEMIA MIELÓIDE AGUDA, DE ACORDO COM O STATUS DE DOENÇA RESIDUAL MÍNIMA POR CITOMETRIA DE FLUXO PRÉ TRANSPLANTE	Ikoma-Colturato MRV, Simioni AJ, Penitenti M, Bortolucci CM, Conti JE, Colturato I, Franceschi FLS, Silva FR, Silva MP, Colturato VAR
12:55 – 13:05	Melhor trabalho em hemoterapia e terapia celular – Establishment of a preclinical model of Burkitt’s lymphoma: evaluating efficacy of CAR-T-CD19 cells.	Pereira MSF, Moço PD, Vaz LD, Fantacini DMC, Mizukami A, Farias KM, Swiech K, Castro VP, Covas DT
13:05 – 13:15	Melhor trabalho em hematologia pediátrica – Perfil clínico, hematológico e genético em uma coorte neonatal com hemoglobinopatia SC	Rezende PDV, Santos MV, Campos GF, Souza MB, Oliveira EL, Almeida JA, Oliveira LMM, Belisário AR, Silva CM, Viana MB
13:15 – 13:25	Melhor trabalho em hemostasia – Deficiência da proteína Arhgap21 acelera processo hemostático em camundongos heterozigotos nocautes	Bernusso VA, Lazarini M, Ferro KV, Vicente CP, Saad STO
13:25 – 13:35	Melhor trabalho em hematologia – Novo composto é capaz de diminuir a produção TNF-α e a adesão de neutrófilos de indivíduos controle e pacientes com Hemoglobinopatia SC "in vitro"	Souza CM, Lanaro C, Melo TR, Saad STO, Santos JLD, Costa FF

Time	Subject	Speaker	Moderator
14:00 – 15:30	ABBVIE – Auditório 3 – Hall E / Térreo		Carlos Sérgio Chiattone
14:00 – 14:10	Opening	Carlos Sérgio Chiattone
14:10 – 14:50	A view of the Future: the role of MRD on the treatment response evaluation in CLL	Francesc Bosch
14:50 – 15:10	Clinical Case	Talita Bueno da Silveira
15:10 – 15:25	Discussion	All
15:25 – 15:30	Closing Remarks	Carlos Sérgio Chiattone
14:00 – 15:30	Immunotherapy in Acute Lymphoblastic Leukemia – Auditório 2 – Térreo	Nicolas Boissel	Vanderson Rocha
	Assessing Minimal Residual Disease in ALL
	Immunotherapy in ALL – what are the possibilities?
	Adolescent/ Adult ALL
	Pediatric ALL
	Clinical Discussion
	Questions and Answers
14:00 – 15:30	LIBBS – Salas 1, 2 e 3 – Andar Superior
14:00 – 14:40	Biosimilars: beyond the clinical aspects	Rony Schaffel
14:40 – 15:10	RTXM83 Trial: Data Report. A proposed biosimilar of Rituximab	Danielle Leão
15:10 – 15:30	Questions
14:00 – 15:30	Bio-Rad – IMMUNOHEMATOLOGY – Salas 7 e 8 – Andar Superior
14:00 – 15:30	Workflow Analysis" for Imuno-hematology: The future is now, are you ready?	Fabian Pohlmann
14:00 – 15:30	Immunohematology complexes cases solved by Blood Group Reference Laboratory (IBGRL) in UK	Paul Shane Grimsley
14:00 – 15:30	Janssen: Redefining Multiple Mieloma History – Auditório 6 – Térreo		Ângelo Maiolino
14:00 – 14:30	Current considerations for non-eligible patients in frontline	Vânia Tietsche de Moraes Hungria
14:30 – 15:00	Optimizing the treatment in RR patients	Francesca Gay
15:00 – 15:30	Discussão
14:00 – 15:30	NOVARTIS: JAKAVI – Auditório 4 – Térreo
14:00 – 14:10	Opening		Nelson Hamerschlak
14:10 – 14:40	Myelofibrosis in Brazil: Updated data on JAKAVI treatment in the Brazilian population (JUMP study)	Laura Fogliatto
14:40 – 15:00	Clinical Cases Presentation	Renato Sampaio Tavares
15:00 – 15:25	Questions & Answers	Todos
15:25 – 15:30	Considerações Finais	Final Remarks
14:00 – 15:30	NOVO NORDISK: Novo Nordisk’s commitment to bleeding management – Auditório 5 – Térreo
14:00 – 14:05	Welcome	Margareth Castro Ozelo
14:05 – 14:25	Bleeding management in acquired haemophilia	Paula Ribeiro Villaça
14:25 – 14:45	Bleeding management in congenital haemophilia with inhibitors	Marília Renni
14:45 – 15:15	Bleeding management in rare bleeding disorders	Sandra Vallin Antunes
15:15 – 15:30	Questions & Answers	Margareth Castro Ozelo
14:00 – 15:30	TAKEDA: Management of iron deficiency and anemia in clinical practice. Sprint or Marathon? – Salas 4 e 5 -Andar Superior		Rodolfo Delfini Cançado e Flávio Naoum
14:00 – 15:30	ASTRAZENECA: Future time perspective for relapsed/refractory mantle cell lymphoma patients treatment: a novel selective second-generation BTK inhibitor – Salas 10 e 11 – Andar Superior		John Pagel
16:00 – 17:30	JANSSEN: How to sequence the treatment of lymphoproliferative diseases – Auditório 6 – Térreo
16:00 – 16:10	Factors for choosing treatment	John Allan
16:10 – 16:20	Fitness-guided treatment	John Allan
16:20 – 16:30	1st Line Treatment Line of CLL	John Allan
16:30 – 16:40	Treatment of R/R patients in the CLL	John Allan
16:40 – 16:50	What to do on the first relapse?
16:50 – 17:00	Role of allogeneic transplantation in
17:00 – 17:10	What to do at high risk patient?
17:10 – 17:20	How to sequence new treatments
17:20 – 17:30	Questions & Answers
16:00 – 17:30	Acute Myeloid Leukemia Update – Auditório 4 – Térreo
16:00 – 16:10	Opening	Eduardo Magalhães Rego
16:10 – 17:00	A new look into AML	Reinaldo Dall Bello
17:00 – 17:15	Clinical Case presentation	Eduardo Magalhães Rego
17:15 – 17:30	Discussion	Todos
	ROCHE: Emicizumab – New Therapeutic Alternative in the Treatment of Hemophilia A with Inhibitor – Auditório 3 – Térreo
16:00 – 16:10	Opening – Emicizumab Efficacy and Safety in studies HAVEN 1 and 2	Luciana Côrrea de Oliveira ( Chair)
16:10 – 16:30	Case 1: Emicizumab administration in Pediatric Patients	Robert Sidonio
16:30 – 16:50	Case 2: Emicizumab administration in Adult Patients	Santiago Bonanad Boix
16:50 – 17:10	Case 3: Brazilian experience with Emicizumab – Stacey Study	Luciana Côrrea de Oliveira ( Chair)
17:10 – 17:25	Round-table	all
17:10 – 17:25	Closing Remarks	Luciana Côrrea de Oliveira ( Chair)
16:00 – 17:30	CELGENE- How to optimize Multiple Myeloma current treatment and what to expect for the future: From Lenalidomide to CAR T- cell		Vânia Hungria
16:00 – 16:05	Introduction
16:05 – 16:30	Considerations in 1st line Multiple Myeloma : treatment in 1st line and post-transplant maintenance	Jairo Sobrinho
16:30 – 16:55	From clinical trials to real life in Multiple Myeloma relapsed/refractory treatment	Danielle Leão
16:55 – 17:20	Is there space for new therapies in Multiple Myeloma? The role of CAR-T cells	Marco Aurélio Salvino
17:20 – 17:30	Q&A
16:00 – 17:20	SANOFI Salas 4 / 5 – Andar Superior
	Studies Outcomes
	Eliglustat on a daily basis: Patient profile and treatment management
16:00 – 17:30	CEI / CERUS: Affordable, Sustainable Blood Safety with Pathogen Inactivation – Salas 1/2/3 – Andar Superior

Time	Subject	Speaker	Moderators
08:30 – 10:00	BLOOD DONATION- Auditório 1 – Térreo		César de Almeida Neto e Maria Angélica de Camargo Soares
08:30 – 08:50	Profile of donors at risk for TRALI	Antonio Fabron Jr
08:50 – 09:10	How to approach blood donors with false-positive results in serological and molecular screening	César de Almeida Neto
09:10 – 09:30	Profile of iron in blood donors	Maria Angélica de Camargo Soares
09:30 – 09:50	Effective strategies for selection of rare donors	Lílian Castilho
09:50 – 10:00	Discussion
08:30 – 10:00	Apheresis – Auditório 3 – Térreo		Alfredo Mendrone Jr. e Marcelo de Carvalho Braga
08:30 – 08:55	Apheresis for lymphocytes collection for immunotherapy of cancer patients (CAR-T cell)	Antonio Sérgio Torloni. e à definir
08:55 – 09:20	PRP: Obtaining and using in surveys	Ângela Luzzo
09:20 – 09:45	Graft-versus-Host Disease: Current Status and Future Vision	Madan Jagasia
09:45 – 10:00	Discussion
11:30 – 12:45	Conferences – Auditório 1 – térreo		Dante Langhi Jr. e Mariângela Moschen
11:30 – 12:00	Arbovirus surveillance in Brazil	Michael Busch
12:00 – 12:30	US FDA transfusion transmitted infections monitoring system (TTIMS)	Michael Busch
12:30 – 12:45	Discussion
11:30 – 12:45	Conferences – Auditório 3 – térreo		José Orlando Bordin e Elyse Moritz
11:30 – 12:00	Human neutrophil antigens	Behnaz Bayat
12:00 – 12:30	Mechanisms of antibody mediated TRALI	Behnaz Bayat
12:30 – 12:45	Discussion
14:45 – 16:00	Conferences – Auditório 1 – Térreo		José Orlando Bordin e Yuri Vasconcelos Pinheiro
14:45 – 15:15	Immunological barriers to blood and platelet transfusions	Petter Höglund
12:00 – 12:30	Blood transfusion management in Myelodysplastic syndromes	Petter Höglund
15:45 – 16:00	Discussion
14:45 – 16:00	Conferences – Auditório 3 – Térreo		Glauco Plens e Luiz de Melo Amorim Filho
14:45 – 15:15	Alloimmunization to red blood cell antigens	Steven R. Sloan
12:00 – 12:30	Next generation sequencing application to transfusion medicine	Connie Westhoff
15:45 – 16:00	Discussion
16:30 – 18:00	Anemia: What is the tolerance limit? – Auditório 1 – Térreo		Kleber Cavalcanti e Maria Stella Figueiredo
16:30 – 16:55	Management of transfusion requirements in the preoperative period	César de Almeida Neto
16:55 – 17:20	Red blood cell transfusion in BMT / Onco-hematology	Denise Menezes Brunetta
17:20 – 17:45	Red blood cell transfusion in critically ill patients	Ana Cristina Silva Pinto
17:45 – 18:00	Discussion
16:30 – 18:00	IMMUNOHEMATOLOGY – Auditório 3 – Térreo		Lílian Castilho e Shirley Castilho
16:30 – 16:50	Case studies using blood group genotyping	Connie Westhoff
16:50 – 17:10	Interpretation and emission of serological and molecular results of variants RH	Lílian Castilho
17:10 – 17:30	Alloantibodies of undetermined specificity: innocent or potentially dangerous	Shirley Castilho
17:30 – 17:50	Transfusion in patients with autoimmune hemolytic anemia	Melca Maria Oliveira Barros
17:50 – 18:00	Discussão

Time	Subject	Speaker	Moderators
08:30 – 10:00	Cell Therapy		Nelson Hamerschlak e Karen de Lima Prata
08:30 – 08:55	Use of genetically-modified cells for inherited and acquired disorders	Valder Arruda
08:55 – 09:20	Cord blood-derived virus-specific T cells for clinical use	Patrick Hanley
09:20 – 09:45	Global overview of the cell therapy: Challenges and Achievements	Dimas Tadeu Covas
09:45 – 10:00	Discussion
11:30 – 12:45	Conferences		Alfredo Mendrone Jr. e Renato Cunha
11:30 – 12:00	CAR T CELLS IN ONCO-HEMATOLOGY: WHERE WE ARE AND WHERE WE GO	Mauro Avanzi
12:00 – 12:30	IMMUNOTHERAPY OF T CELLS FOR LEUKEMIA	Patrick Hanley
12:30 – 12:45	Discussion
14:45 – 16:00	Conferences		Vanderson Rocha e Andrea Kondo
14:45 – 15:15	Harnessing T-Cell Function for Adoptive T-Cell Therapy	Renato Cunha
15:15 – 15:45	Use of T-Cells for Virus Infection	Patrick Hanley
15:45 – 16:00	Discussion
14:45 – 16:00	Conferências		Vanderson Rocha e Andrea Kondo
14:45 – 15:15	Avanços e novas aplicações na terapia adotiva com células T	Mauro Avanzi
15:15 – 15:45	Uso de células T para infecções virais	Patrick Hanley
15:45 – 16:00	Discussion
16:30 – 18:00	Cell Therapy		Ângela Luzo e Lúcia Mariano da Rocha Silla
16:30 – 16:50	Production of dendritic cells. Clinical applicability	José Alexandre Barbuto
16:50 – 17:10	Bone Marrow or Peripheral Blood as a HPC source: Which one to choose?	Alfredo Mendrone Jr.
17:10 – 17:30	GENE THERAPY IN SICKLE CELL DISEASE	Marina Cavazzana
17:30 – 17:50	Avanços e novas aplicações na terapia adotiva com células T	Mauro Avanzi
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	How do I treat ALL and AML ( Auditório 5 – Térreo )		Evandro Maranhão Fagundes e Rosane Isabel Bittencourt
08:30 – 08:50	Managing Asparaginase in the treatment of Acute Lymphoblastic Leukemia	Dan Douer
08:50 – 09:10	New Target Therapies for AML	à definir
09:10 – 09:30	BMT indication in AML: importance of molecular markers	Eduardo Magalhães Rego
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	IGF1R and IGF2R expression predicts outcomes and represents a target therapy in acute promyelocytic leukemia	Coelho-Silva JL, Machado-Neto JA, Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Melo RA, Bittencourt R, Pasquini R, Pagnano KB, Fagundes EM, Chauffaille ML, Chiattone CS, Rego EM, Traina F ( Autores )
09:40 – 09:50	FOXO3A is downregulated in Acute Promyelocytic Leukemia and Metformin treatment is effective against ATRA-resistant APL cells	Pereira-Martins DA, Rojas CAO, Neto PLF, Weinhauser I, Koury LC, Bittencourt R, Pagnano K, Fagundes EM, Lucena-Araujo A, Rego EM ( Autores )
09:50 – 10:00	Discussion
08:30 – 10:00	Health Policies: Availability of medication access with the support of SBOC ( Auditório 6 – Térreo )		José Francisco Comenalli Marques Jr. e Denys Eiti Fujimoto
08:30 – 08:50	Role of AMB and Specialty Medical Societies for patients' access to medication	Ângelo Maiolino
08:50 – 09:10	New Target Therapies for AML	à definir
09:10 – 09:30	Access to Medication for the Oncology Patient	Cinthya Sternberg
09:30 – 09:50	Scientific Works – Oral Presentations
09:50 – 10:00	Discussion
11:30 – 12:45	Conferences		Carlos Sérgio Chiattone e Valéria Buccheri
11:30 – 12:00	Peripheral T cell Lymphomas: What is new in 2018 ?	Steven Horwitz
12:00 – 12:30	Advances in the treatment of classical Hodgkin Lymphoma	Otávio Baiocchi
12:30 – 12:45	Discussion
11:30 – 12:45	Conferences ( Auditório 6- térreo )		Silvia M. M. Magalhães e Carmino Antonio de Souza
11:30 – 12:00	MYELODYSPLASTIC SYNDROME AFTER FIRST-LINE THERAPIES FAILLURE – WHAT'S NEXT?	Valéria Santini
12:00 – 12:30	How the advancement of the methodologies to study the genome have contributed to the improvement of the understanding of the biology and treatment of Chronic Myeloid Leukemia	Giuseppe Saglio
12:30 – 12:45	Discussion
14:45 – 16:00	Conferences ( Auditório 5 – Térreo )		Carlos Sérgio Chiattone e Rodrigo Calado
14:45 – 15:15	How should we sequence and combine novel therapies in CLL?	Francesc Bosch
15:15 – 15:45	Role of transplantation in the treatment of immune aplastic anemia in 2018	Regis Peffault de Latour
15:45 – 16:00	Discussion
14:45 – 16:00	Conferences ( Auditório 6 – Térreo )		Vaneuza Araújo Moreira Funke e Laura Fogliatto
14:45 – 15:15	Myeloproliferative Neoplasms – JAK/STAT Signalling and Stem Cell Subversion	Tony Green
15:15 – 15:45	Is HSCT still necessary in Ph+ ALL	Oliver Ottmann
15:45 – 16:00	Discussion
16:30 – 18:00	Non-Hodgkin Lymphoma ( Auditório 5 – Térreo )		Carlos Sérgio Chiattone e Gisele Wally Braga Colleoni
16:30 – 16:50	Mantle Cell Lymphoma: What is New in Treatment	Samir Kanaan Nabhan
16:50 – 17:10	First line treatment in DLBCL: Is R-CHOP still the standard?	Jorge Vaz Pinto Neto
17:10 – 17:30	R/R Follicular Lymphoma: Current Treatment Strategy	Rony Schaffel
17:30 – 17:50	Scientific Work – Oral Presentation
17:30 – 17:40	Investigação dos mecanismos celulares envolvidos na apoptose induzida por uma plastoquinona natural em células de neoplasias linfoides	Santos-Pirath IM, Walter LO, Maioral MF, Philippus AC, Falkenberg MB, Santos-Silva MC ( Autrores )
17:40 – 17:50	Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elder	Poles WA, Nishi EE, Oliveira MB, Eugênio A, Andrade T, Campos AHFM, Júnior RRC, Vassallo J, Alves AC, Neto CS, Paes RAP, Landman G, Zerbini MCN, Colleoni GWB ( Autores )
17:50 – 18:00	Discussion
16:30 – 18:00	Myeloproliferative Neoplasms ( Auditório 6 – Térreo )		Fernanda Seguro e Alexandre Nonino
16:30 – 16:50	Discontinuation of CML treatment: should it be incorporated into clinical practice? Pros and Cons	Kátia Borgia Barbosa Pagnano e Israel Bendit
16:50 – 17:10	Molecular and clinical findings in familial myeloproliferative neoplasms	Isabelle Plo
17:10 – 17:30	Rare Myeloproliferative Neoplasms	Fabíola Traina
17:30 – 17:50	Scientific Work – Oral Presentation
17:30 – 17:40	Estudo ambispectivo comparando eficácia e segurança de Glivec® vs. imatinibe genérico na Leucemia Mieloide Crônica em fase crônica – análise da adesão ao tratamento	Reis SRCD, Miranda ECM, Magalhães GHR, Clementino NCD, Hauck LM, Seguro FS, Bendit I, Fogliatto LM, Torriani MS, Centrone RT, Novaes JSI, Rosa PCP, Paula EV, Souza CA, Pagnano KBB ( Autrores )
17:40 – 17:50	Análise da expressão de RNAs longos não codificantes (LncRNA) em linhagens celulares de Leucemia Mielóide Crônica: impactos na resistência a múltiplas drogas	Poralla G, Rumjaneck V, Pizzatti L ( Autores )
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Acute Myeloid Leukemia Pediatric in our Setting: Continuous Challenges (Salas 7/8 – Mezanino)		Soraia Rouxinol e Marcelo Milone
08:30 – 08:50	Acute Promyelocytic Leukemia in the arsenic age	Daniel Freigeiro
08:50 – 09:10	Treatment of AML in Developing Countries	à definir
09:10 – 09:30	Are we ready for contemporary LMA protocols?	Amilcar Cardoso
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Análise retrospectiva de pacientes pediátricos com leucemia mielóide aguda de 2006 a 2016: Experiência de um centro único — Instituto Nacional de Câncer (INCA)	Monteso KCA, Apa AG, Gonzaga YBM, Dobbin JA, Carrio MKS, Matos RRC, Silva MLM, Gomes BE, Amaral NC ( Autores )
09:40 – 09:50	Complicações trombóticas na leucemia promielocítica aguda pediátrica	Antunes AA, Monteiro CN, Celeste DM, Garanito MP, Cristofani LM, Filho VO, Carneiro JDA ( Autores )
09:50 – 10:00	Discussion
08:30 – 10:00	Thrombosis in Pediatrics (Salas 10/11 – Mezanino)		Andrea Thives de Carvalho Hoepers e Saide Trindade
08:30 – 08:50	Thrombophilia: what evidence do we have in pediatrics	Jorge David Aivazoglou Carneiro
08:50 – 09:10	Manejo da trombose venosa relacionada ao cateter	Priscila Grizante
09:10 – 09:30	Post-thrombotic syndrome	Júlia Maimone
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	ESTUDO DOS PARÂMETROS PLAQUETÁRIOS EM RECÉM-NASCIDOS ATENDIDOS NA MATERNIDADE NOSSA SENHORA DE LOURDES EM ARACAJU/SE	Andrade MM, Santos MSD, Oliveira TTA, Oliveira RIS, Nascimento BKS, Souza ICL ( Autores )
09:40 – 09:50	Factor V Leiden and Prothrombin mutation prevalence evaluation on a large diagnostic laboratory	Rizzato VR, Feres MC, Junior GS, Souza AA, Boscoli DR, Martino MC, Vicari P, Tufik S ( Autores )
09:50 – 10:00	Discussion
11:30 – 12:45	Pediatric lymphomas and current issues (Salas 7/8 – Mezanino)		Gabriele Zamperlini Netto e Melissa Ferreira de Macedo
11:30 – 12:00	Immunotherapy in Pediatric Lymphomas: improving the chances of cure or delaying relapse	Lilian Cristofani
12:00 – 12:30	Role of allogeneic BMT in relapsed Hodgkin's lymphoma	Victor Gottardello Zecchin
12:30 – 12:45	Discussion
11:30 – 12:45	Management of thrombosis under risk (Salas 10/11 – Andar Superior)		Júlia Maimone e Miriam Park
11:30 – 12:00	Thrombolysis in Pediatrics	Priscila Grizante
12:00 – 12:30	Anticoagulation in patients with mechanical circulatory support	Leonardo Brandão
12:30 – 12:45	Discussion
14:45 – 16:00	Conferences (Salas 7/8 – Mezanino)		Anita Frisanco e Ana Paula Freund
14:45 – 15:15	Current characterization of JMML	Luiz Fernando Lopes
15:15 – 15:45	JMML: Current Therapeutic Strategies x Subtypes	Maria Lúcia M. Lee
15:45 – 16:00	Discussion
14:45 – 16:00	Management of patients with hemorrhagic disorders (Salas 10/11 – Mezanino)		Mônica Pinheiro de Almeida Veríssimo e Paula Bruniera
14:45 – 15:25	Perioperative Management of Coagulation Disorders	Jorge David Aivazoglou Carneiro
15:25 – 15:55	Management of coagulopathy in children with liver diseases	Christiane Maria Silva
16:30 – 18:00	Immunotherapy in the treatment of pediatric ALL (Salas 7/8 – Mezanino)		Luiz Fernando Mantovani e Renato Guedes
16:30 – 16:50	Indications of Blinatumomab and difficulties in management	Cláudio Galvão de Castro Jr.
16:50 – 17:10	Experience and outcomes with the use of Blinatumomab in our environment	Adriana Seber
17:10 – 17:30	CAR T in ALL: reality or utopia in Latin America?	Nelson Hamerschlak
17:30 – 17:40	Scientific Works – Oral Presentations
17:30 – 17:40	Blinatumomab use in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia from an open-label, multicenter, expanded access study	Locatelli F, Zugmaier G, Vora A, Rossig C, Peters C, Brethon B, Obrien M, Belton L, Handgretinger R ( Autores )
17:40 – 17:50	Alterações Oftalmológicas em Leucemia Linfoblástica Aguda: uma Coorte de Cinco Anos	Mendonca CQ, Freire MV, Tavares MKGS, Silva WMA, Alencar CG, Cipolotti R ( Autores )
17:40 – 18:00	Discussion
16:30 – 18:00	Treatment of thrombosis in pediatrics (Salas 10/11 – Mezanino)		Isa Lyra e Priscila Grizante
16:30 – 16:50	Treatment of arterial thrombosis	Soraia Rouxinol
16:50 – 17:10	Treatment of thrombosis in unusual sites	Daniele Celeste
17:10 – 17:30	Treatment of ischemic stroke	Leonardo Brandão
17:30 – 17:40	Scientific Works – Oral Presentations
17:30 – 17:40	MONITORIZAÇÃO TERAPÊUTICA DA VARFARINA ATRAVÉS DO TTR	Oliveira KM, Negreiros CCA, Rodrigues JS, Souza MFS, Freitas VC, Santos END, Gomes ABD, Soares RDA, Junior FAAES, Rebecchi IMM ( Autores )
17:40 – 17:50	Manejo de trombocitopenia induzida por heparina (HIT) com rivaroxabana, em peri-transplante autólogo de medula óssea	Ribeiro CDES, Rothschild C, Okazaki E, Valim AKZ, D'amico EA, Atanazio M, Filho JS, Rocha V, Villaca PR ( Autores )
17:40 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-table: Hemostasis laboratory ( Auditório 2 – Hall E / Térreo )		Fernanda Orsi e Silmara Montalvão
08:30 – 08:50	DOAC monitoring: what does the lab offer?	João Carlos Campos Guerra
08:50 – 09:10	Diagnosis and monitoring of hemophilia treatment: what can the lab tell us?	Silmara Lima Montalvão
09:10 – 09:30	Laboratory diagnosis of APS	Stephan Moll
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Pacientes com tromboembolismo venoso mesmo na fase tardia apresentam ativação e liberação de redes extracelulares de neutrófilos (NETs)	Zapponi KCS, Orsi FLA, Brito IR, Júnior JLRC, Montalvão SAL, Penteado CFF, Paula EV, Sckayer LFB, Annichino-Bizzacchi JM ( Autores )
09:40 – 09:50	The impact of antibody profile associated with antiphospholipid syndrome and thrombosis is dependent of laboratory platform	Fernandes MCGL, Delima-Montalvão SA, Soares SMS, Huber SC, Orsi F, Depaula EV, Yamaguti GG, Colella MP, Annichinno-Bizzacchi JM ( Autores )
09:50 – 10:00	Discussion
11:30 – 12:45	Conferences ( Auditório 2 – Hall E / Térreo )		Suely Meireles Rezende e Alessandra Prezotti
11:30 – 12:00	New treatment modalities in Hemophilia	Margareth Castro Ozelo
12:00 – 12:30	Gene therapy in Hemophilia	Valder Arruda
12:30 – 12:45	Discussion
14:45 – 16:00	Conferences ( Auditório 2 – Hall E / Térreo )		Joyce Annichino-Bizzacchi e Daniel Dias Ribeiro
14:45 – 15:15	Treatment of venous thromboembolism in the era of DOACs	J Beyer-Westendorf
15:15 – 15:45	Laboratory monitoring of oral anticoagulation with DOACs: when, how and why?	Dayse Maria Lourenço
15:45 – 16:00	Discussion
16:30 – 18:00	Round-table: Consultative Hemostasis ( Auditório 2 – Hall E / Térreo )		Luciana Côrrea de Oliviera e Erica Okazaki
16:30 – 16:50	Thrombophilia investigation in patients with placenta-mediated pregnancy complications: the obstetrician`s point of view	Maria Rita de Figueiredo Lemos Bortollo
16:50 – 17:10	Thrombophilia investigation in patients with placenta-mediated pregnancy complicaitons: the hematologist`s point of view	Joyce Annichino-Bizzacchi
17:10 – 17:30	Catastrophic Antiphospholipid Syndrome	Elbio Antonio D’Amico
17:30 – 17:40	Scientific Works – Oral Presentations
17:30 – 17:40	Avaliação de biomarcadores da disfunção endotelial e sua associação com a função do enxerto em receptores do transplante renal	Martins SR, Alves LV, Neris CC, Duarte RCF, Junior FDML, Dusse LMS, Alpoim PN, Mota APL ( Autores )
17:40 – 17:50	Clinical course of primary immune thrombocytopenia with positive antiphospholipid antibodies	Cruz ACL, Saraiva S, Hayakawa GGY, Paula EV, Annichino-Bizzacchi JM, Orsi FA ( Autores )
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-Table Hereditary Anemias ( Auditório 4 – Hall E / Térreo )		Perla Vicari e Bruno Benites
08:30 – 08:50	Unstable hemoglobins: from clinical practice to identification	Sandra Fátima Menosi Gualandro
08:50 – 09:10	Bypassing transfusion difficulties in patients with sickle cell disease	Carla Luana Dinardo
09:10 – 09:30	Vaccination in adults with sickle cell disease	Guilherme Henrique Hencklain Fonseca
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Pode o aumento do átrio esquerdo ser considerado marcador precoce de gravidade na anemia falciforme?	Leonel RB, Bernal DAO, Jacinto MP, Campos MRS, Figueiredo MS ( Autores )
09:40 – 09:50	A hemólise aguda induz processos inflamatórios e angiogênicos in vivo	Gotardo EMF, Chweih H, Brito PL, Costa R, Soares R, Costa FF, Conran N ( Autores )
09:50 – 10:00	Discussion
11:30 – 12:45	Conferences: Sickle cell disease ( Auditório 4 – Hall E / Térreo )		Maria Stella Figueiredo e Aderson da Silva Araújo
11:30 – 12:10	Microparticles as a marker of sickle cell disease	Fernando Ferreira Costa
12:10 – 12:40	BMT in sickle cell disease: what is new?	Vanderson Rocha
12:40 – 12:45	Discussion
14:45 – 16:00	Conferences: Hereditary Anemias ( Auditório 4 – Hall E / Térreo )
14:45 – 15:15	Treatment of ineffective erythropoiesis	Stefano Rivella
15:15 – 15:45	Molecular bases of Congenital dyserythropoietic anaemia	Roberta Russo
15:45 – 16:00	Discussion
16:30 – 18:00	Round-table: Novel treatments ( Auditório 4 – Hall E / Térreo )		Martha Mariana Arruda e Clarisse Lopes de Castro Lobo
16:30 – 16:50	HHT and anti-vEGF use	Aderson da Silva Araújo
16:50 – 17:10	Simvastatin in sickle cell anemia	Bruno Benites
17:10 – 17:30	Metformin for bone marrow fibrosis	Paula de Melo Campos
17:30 – 17:50	Scientific Works – Oral Presentations
17:30 – 17:40	Efeitos do inibidor de agregação plaquetária – prasugrel, no processo vaso-oclusivo em camundongos com anemia falciforme	Chweih H, Silva JAF, Brito PL, Gotardo EMF, Garcia F, Junior WAF, Leonardo FC, Franco-Pentado CF, Costa FF, Conran N ( Autores )
17:40 – 17:50	HEME INDUCES PLATELET ADHESION VIA ACTIVATION OF THE αIIbβ3 INTEGRIN	Teles LIM, Torres LS, Leonardo FC, Costa FF, Conran N ( Autores )
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-table: Clinical significance of immunophenotypic findings in cerebrospinal fluid in ALL (12/13 Piso Superior)		Nydia Strachman Bacal e Vicente Odone Filho
08:30 – 08:50	Cytometry	Rodrigo de Souza Barroso
08:50 – 09:10	Cerebrospinal fluid in adult ALL	Belinda Pinto Simões
09:10 – 09:30	Cerebrospinal fluid in pediatrics ALL	Maria Lúcia de Martino Lee
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Análise dos testes de crossmatching plaquetário por citometria de fluxo (PIFT) dos pacientes com suspeita de refratariedade plaquetária atendidos pela Fundação Pró-Sangue/ Hemocentro de São Paulo	Barbato FB, Kuniyoshi AM, Cardoso R, Bonifácio SL, Conrado M, Oliveira VB, Dezan MR, Rocha V, Mendrone-Junior A, Dinardo CL ( Autores )
09:40 – 09:50	Eritrodermia: Elevada Sensibilidade e Valor Preditivo Negativo da Triagem para Doença Linfoproliferativa T por Citometria de Fluxo Utilizando 6 Anticorpos Monoclonais	Siqueira LG, Oechsler HLS, Silva MCA, Barroso RS, Maciel FVR, Herculani JECC, Reis CRMD, Martins MT, Ribeiro JCC, Sales MM ( Autores )
09:50 – 10:00	Discussion
14:45 – 16:00	Conferences – Immunodeficiencies and autoimmune diseases (12/13 Piso Superior)		Miriam Beltrame e Mirtes M. Sales
14:45 – 15:15	Autoimmune diseases diagnosis	Luis Eduardo Andrade
15:15 – 15:45	Immunodeficiencies diagnosis by cytometry	Elaine Sobral
15:45 – 16:00	Discussion

Time	Subject	Speaker	Moderators
11:30 – 12:45	Conference: The lab in rare diseases		Lígia Niero Melo e Kleber Fertrin
11:30 – 12:00	Laboratory evaluation of paroxysmal nocturnal hemoglobinuria	Lucas Cantadori
12:00 – 12:30	Laboratory evaluation of hemophagocytic syndrome	Cristina Bortolheiro
12:30 – 12:45	Discussion
16:30 – 18:00	Round-table: Hematologic abnormalities in Internal Medicine: pathophysiological view through peripheral blood and bone marrow evaluation		Kleber Fertrin, Lígia Niero Melo e Cristina Bortolheiro
16:30 – 16:50	How I evaluate cytopenias with splenomegaly
16:50 – 17:10	How I evaluate thrombocytosis
17:10 – 17:30	How I evaluate anemia in the inpatient setting
17:30 – 17:40	Scientific Works – Oral Presentations
17:50 – 18:00	Discussion

Time	Subject	Speaker	Moderators
08:30 – 18:00	22nd National Symposium on Blood Donors Recruitment		Alfredo Mendrone Jr, Eugênia Maria Amorim Ubiali, José Francisco Comenalli Marques Jr., Junia Guimarães de Mourão Cioffi
08:30 – 09:00	Challenges for donors recruitment in 2018	Mônica de Castro Leite Silveira Meirelles	Mônica de Castro Leite Silveira Meirelles
09:00 – 09:30	New trends for Blood Donors Recruitment Communication	Doris Sandoval Lavorat	Mônica de Castro Leite Silveira Meirelles
09:30 – 10:30	Challenge of advertising agencies in donors’ recruitment	Helber Frasson	Mônica de Castro Leite Silveira Meirelles
10:30 – 10:45	Break
10:45 – 11:15	Recruiter dilemma	Heloisa Maria Dias de Oliveira Gontijo	Doris Sandoval Lavorat
11:15 – 11:45	Effectiveness in the Strategy for Donor's Loyalty and Motivation	Nágela Maria Lima de Olivieira	Doris Sandoval Lavorat
11:45 – 12:30	Blood Donation in Companies: An Experience within the Quality of Life Program	Regina Helena do Nascimento Paron	Doris Sandoval Lavorat
12:30 – 14:30	Pause for Lunch
14:45 – 15:45	Digital Influencers	Liliane Ferrari	Heloisa Maria Dias de Oliveira Gontijo
15:45 – 16:15	Importance of partnerships in donors’ recruitment	Kelly Cristina Borges	Heloisa Maria Dias de Oliveira Gontijo
16:15 – 16:30	Break
16:30 – 17:00	Status of donor recruitment for Bone Marrow Transplantation	Fabiane Natal Janata	Roberta Aparecida dos Santos
17:00 – 17:30	Humanization and Assistance to volunteer blood donor	Rafael José da Silva	Roberta Aparecida dos Santos
17:30	Closing

Time	Subject	Speaker	Moderators
08:30 – 08:45	Opening Oficial		Ana Paula Queiroz, Carolina Ferreira, Daniela Archanjo e Mariana Lazarini
08:50 – 09:40	Round-table: Studies with derivatives of medicinal herbs or other natural compounds for the treatment of hematological diseases
08:50 – 09:10	Challenges faced in transforming plants into drugs	Mary Ann Foglio
09:10 – 09:30	Natural products as epigenetic modulators in myeloid neoplasias	Marisa Alvarez
09:30 – 09:40	Perguntas/Discussion
09:45 – 10:05	Palliative care in hematology
	Participation of the pharmacist in the palliative care team	Bianca Angelie Cerretti Mendrot
10:15 – 11:15	Scientific Works – Guided Visit
11:15 – 11:30	Break
11:30 – 12:45	Round-table: Tests and development of novel drugs: clinical and pre-clinical trials
11:30 – 11:50	Pre-clinical trial of novel drugs for the treatment of blood disorders	João Machado-Neto
11:50 – 12:10	linical trial of novel drugs for the treatment of blood disorders	Tatiana Iervolino Ricca
12:10 – 12:30	Innovations in immunotherapy up to CAR-T Cells	Jefferson Silva Martins
12:30 – 12:45	Perguntas/Discussion
12:45 – 14:30	Pause for Lunch
14:45 – 15:30	Round-table: Hemophilia outpatient
14:45 – 15:05	How do I work as a pharmacist in the hemophilia outpatient clinic?	Cassio Fabricio dos Santos
15:05 – 15:25	What is the government role in the hemophilia outpatient clinic	Luciene Figueiredo
15:25 – 15:35	Perguntas/Discussion
15:40 – 16:00	Pharmacosurveillance in hematological patients – from data collection to notification	Cintia de Oliveira Sousa/Alan Alves dos Santos
16:00 – 16:15	Break
16:15 – 16:35	The Clinical Pharmacist performance in Bone Marrow Transplantation	Danilo Ponciano
16:35 – 17:25	Scientific Works – Oral Presentations
16:35 – 16:45	Avaliação de prescrições pediátricas de hidroxiuréia para pacientes com doença falciforme	Autores: Duque FAT, Dias EF, Costa JM, Rodrigues PC
16:45 – 16:55	Ensaio de equivalência farmacêutica em medicamentos disponíveis no mercado brasileiro contendo mesilato de imatinibe	Autores: Reis SRCD, Pagnano KBB, Miranda ECM, Souza CA, Rosa PCP
16:55 – 17:05	Molecular epidemiology of multiresistant Staphylococcus epidermidis isolated from health professionals at a Hematology and Hemotherapy Center	Autores: Ferreira CM, Filho RAAB, Ferreira GMA, Cristo DA, Souza VS, Silva LM, Barbosa TC, Fraiji NA, Ferreira WA
17:20 – 17:40	Management strategies in the acquisition of drugs
17:20 – 17:35	Management strategies in the acquisition of onco-hematological drugs in RJ	Ana Paula Queiroz
17:35 – 17:50	Elaboration of a final draft for ABHH on strategies for the acquisition of onco-haematological drugs
17:50 – 18:00	Closing

Time	Subject	Speaker	Moderators
08:30 – 08:40	Opening Oficial	Walmyr Ribeiro Mello
08:40 – 09:50	Module I Coagulopathies		Luiz Antônio de Souza
08:40 – 09:10	Effectiveness of topical local hemostatic media in the control and prevention of bleeding in the oral cavity in patients with hereditary coagulopathies.	Vinicius Rabelo Torregrossa
09:10 – 09:40	Risk and bleeding supplementation in anticoagulated patients: Emergency treatment	Erica Okazaki
09:40 – 09:50	Discussion
09:50 – 10:40	What the Dentist should know about new therapies for the treatment of lymphomas – Multidisciplinary approach with novel therapies for lymphoma treatment	Luiz Alberto Valente Soares Junior	Eduardo Lima Pádua
10:40 – 11:05	Break / Panel Assesment		Thais Barreto, Paulo Sérgio da Silva Santos, Walmyr Ribeiro Mello and Cleber Alexandre
11:05 – 12:45	Module II Onco-hematology		Héliton Spindola Antunes
11:05 – 11:35	Successful Cases: Dental management of patients with hemoglobinopathies.	Luiz Alberto Valente Júnior
11:35 – 12:05	Oral manifestations in lymphoma	Walmyr Ribeiro Mello
12:05 – 12:35	Proficiency of dentistry	Rosana Claudia Scramin Wakim	Paulo Sérgio da Silva Santos
12:35 – 12:45	Discussion
12:45 – 14:45	Pause for Lunch
14:45 – 15:45	Presentation of clinical cases
14:45-14:55	O papel da imunofenotipagem por citometria de fluxo no diagnóstico de lesões neoplásicas hematológicas em boca: relato de dois casos clínicos	Saquet P, Munhoz EA, Cardoso CC, Santos-Silva MC, I-Ching L, Del-Moral JAG, Grando LJ, Lisboa ML, Camargo AR ( Autores )	Rogério Caldas
15:00 – 15:10	Plasmocitoma Mandibular: Aspectos Não Usuais De Cura Óssea Depois De Quimioterapia.	Degang-Silveira J, Mitt VC, Lisboa ML, Zimmermann C, Bonfim AMDS, Moral JAGD, Grando LJ	Frederico Buhatem Medeiros
15:15 – 15:25	Edema cervical com obstrução parcial de vias aéreas após anestesia odontológica troncular em paciente Hemofílico com inibidor: relato de caso.	Reis TC, Ferrari TC, Bataglion C, Brandao C, Oliveira LCO, Inoccentini LMAR, Macedo LD ( Autores )	Héliton Spindola Antunes
15:45 – 17:00	MODULE III HSCT		Fabiana Granzotto
15:45 – 16:15	Evaluation of salivary proinflammatory cytokines in patients submitted to HSCT and oral laser therapy	Geisa B. L. da Silva
16:15 – 16:30	Break
16:30 – 17:00	Concept of TCTH Haploidentico	Adriana Seber
17:00 – 17:20	The impact of CAR T-cell therapy on current dental care protocols – CAR T-cell therapy toxicity on oral tissues	Vanderson Rocha
17:20 – 17:30	Discussion
17:30 – 18:00	ABHH Dental Committee Assembly	Perla Shitara

Time	Subject	Speaker	Moderators
13:00 – 14:30	ABBVIE – Panel Specialists – Auditório 3 – Hall E / Térreo		Celso Arrais
13:00 – 13:05	Opening	Celso Arrais
13:05 – 13:35	The new era of CLL therapy: BCL-2 blockage as target therapy and the evolution of response evaluation	Francesc Bosch
13:35 – 14:05	CLL patient management in the era of target-therapy	Matthew Davids
14:05 – 14:20	Clinical Case	Celso Arrais e Matthew Davids
14:20 – 14:30	Discussion	Celso Arrais
13:00 – 14:30	ALEXION: PNH: What have we learned after 10 years of complement inhibition experience – Salas 7 / 8 – Andar Superior
13:00 – 13:05	Introduction and objectives	Phillip Scheinberg
13:05 – 13:15	Physiopathology, diagnosis & high risk groups	Phillip Scheinberg
13:15 – 13:40	PNH treatment, High disease activity & Clinical Case (Classic PNH)	Gérard Socié
13:40 – 14:05	PNH in the context of BMF & Clinical Case (PNH in the context of BMF)	Gérard Socié
14:05 – 14:30	Questions & Answers	Todos
14:30	Closing remarks	Phillip Scheinberg
13:00 – 14:30	AMGEN: Individualizing Therapeutic Strategies for Patients With Relapse Refractory Multiple Myeloma – Salas 1, 2 e 3 – Mezanino		Vânia Hungria
13:00 – 13:15	Second generation Proteasome inhibitors for Relapsed Refractory Multiple Myeloma treatment	Vânia Hungria
13:15 – 13:45	How Do I Treat Patients with Relapse Refractory Multiple Myeloma?	Rafael Fonseca
13:45 – 14:15	Comprehensive care for patients with multiple myeloma: cardiovascular health considerations	Ajai Chari
13:00 – 14:30	GRIFOLS – SAFETY AND EFFICIENCY APPLIED TO TRANSFUSIONAL MEDICINE – Auditório 2 – Térreo
	Clinical efficacy and in vitro quality parameters of platelet concentrates preserved in platelet additive solutions (PAS)	Dirk de Korte
	The benefits of automation in Immunohematology – Experience with the new Eflexis System	Christopher Elliot
13:00 – 14:30	SHIRE – Updates on hemophilia treatment – Salas 12/13 – Mezanino		Margareth Castro Ozelo
13:00 – 13:20	Overview of hemophilia treatment in Brazil: where are we?	Alessandra Prezotti
13:20 – 13:50	Treatment of patients with hemophilia who develop inhibitors	Marijke Van Den Berg
13:50 – 14:15	Individualization of treatment in patients with hemophilia	Margareth Castro Ozelo
14:15 – 14:30	Questions and Answers
13:00 – 14:30	LIBBS – Salas 4 / 5 – Andar Superior
13:00 – 14:10	Chemotherapy waste and ideal size of bortezomib vial	Jairo Sobrinho
14:10 – 14:30	Questions
13:00 – 14:30	TAKEDA: Achieving successes in the patient's journey with haematological pathologies CD30 + – Auditório 1 – Térreo
13:00 – 13:05	Openning	Nelson Spector
13:05 – 13:25	Strategies to optimize results for patients with Hodgkin's lymphoma R/R	Otávio Baiocchi
13:25 – 13:40	Improving outcomes for patients with ALCL R/R	Laura Fogliatto
13:40 – 14:20	New perspectives for patients with cutaneous lymphomas	Steven Horwitz
14:20 – 14:30	Q&A	Steven Horwitz
13:00 – 14:30	NOVARTIS: Aplastic Anemia Updates – Auditório 4 – Térreo
13:00 – 13:10	Opening	Rodrigo Calado
13:10 – 14:00	Severe Aplastic Anemia 1st line: Changing patient journey	Regis Peffault De Latour
14:00 – 14:15	Clinical Case presentation	Rodrigo Calado
14:15 – 14:30	Discussion	Todos
13:00 – 14:30	ZODIAC: Debate sobre o diagnóstico e tratamento de VOD/SOS – Sala 10/11 – Andar Superior	Belinda Pinto Simões, Vanderson Rocha, Nelson Hamerschlak e Vicente Odone Filho
13:00 – 14:30	STAGO: Importance of Diagnosis and Prediction of Thrombotic Diseases – Auditório 5 – Térreo
13:00 – 13:05	Introduction	Presidente: Daniel Dias Ribeiro
13:05 – 13:45	Clinical Use of D-dimer in Venous Thromboembolism	Stephan Moll
13:45 – 14:20	Prediction of VTE in cancer patients	Daniel Dias Ribeiro
14:20 – 14:30	Final Remarks	Daniel Dias Ribeiro e Stephan Moll

Time	Subject	Speaker	Moderators
08:30 – 10:00	Transfusion transmitted disease – Auditório 1 – Térreo		José Eduardo Levi e Ester Cerdeira Sabino
08:30 – 08:55	Metagenomics: use in hemotherapy	José Eduardo Levi
08:55 – 09:20	Zika vírus RNA and antibody dynamics and infectivity	Michael Busch
09:20 – 09:45	Emerging viral infections in hemotherapy and hematopoietic stem cell transplantation	Svetoslav Slavov
09:45 – 10:00	Discussion
08:30 – 10:00	Apheresis – Auditório 3 – Térreo		Alfredo Mendrone Jr.
08:30 – 08:55	Levels of evidence on indications for therapeutic apheresis: what is changing?	Marisa Marques
08:55 – 09:20	Cost-effectiveness of platelet collection: apheresis vs. Buffy-coat vs. random pool	Alfredo Mendrone Jr.
09:20 – 09:45	Plasma collection from animals for vaccine production	José Francisco Comenalli Marques Jr.
09:45 – 10:00	Discussion
08:30 – 10:00	TRANSFUSION REACTIONS – Salas 14 / 15 – Andar Superior		Joselito Bomfim Brandão e Toebaldo Antônio de Carvalho
08:30 – 08:55	Post-transfusional sepsis	Eugênia Maria Amorim Ubiali
08:55 – 09:20	Febrile non-hemolytic reaction: what's new?	Melca Maria Oliveira Barros
09:20 – 09:45	Immune hemolysis	Carolina Bub
09:45 – 10:00	Discussion
11:30 – 13:00	TRANSFUSIONAL MEDICINE – Auditório 1 – Térreo		Edmir Boturão Neto e Denys Eiti Fujimoto
11:30 – 11:50	Platelets: room temperature, refrigerated or cryopreserved	Dante Langhi Jr.
11:50 – 12:10	Massive Transfusion	Fabrício Biscaro Pereira
12:10 – 12:30	Production of cells in laboratory	Dimas Tadeu Covas
12:30 – 12:50	Recombinant coagulation factors and new products: clinical results	Sandra Vallin Antunes
12:50 – 13:00	Discussion
11:30 – 13:00	Immunohematology – Auditório 3 – Térreo		Carla Luana Dinardo e Lílian Castilho
11:30 – 11:50	Use of basic techniques of molecular biology in the resolution of complex cases in immunohematology	Bruno Ribeiro Cruz
11:50 – 12:10	Role of cell assays in determining the clinical significance of irregular alloantibodies	Carla Luana Dinardo
12:10 – 12:30	External quality control or proficiency testing for blood group antigen genotyping	Lílian Castilho
12:30 – 12:50	The use of molecular testing in blood bank	Steven R. Sloan
12:50 – 13:00	Discussion
11:30 – 13:00	ETHICS IN HEMOTHERAPY – Auditório 3 – Térreo		José Francisco Comenalli Marques Jr. e Benedito de Pina Almeida Prado Jr.
11:30 – 11:55	The right of the legislator to impose restrictions on the donation of blood, organs and tissues: what is the limit?	Benedito de Pina Almeida Prado Jr.
11:55 – 12:20	Rights of the pacient: refusal of blood transfusion and exposure to risk of contamination. Is there a limit?	Christine Santini
12:20 – 12:45	Hemotherapy guidelines: critical analysis	Helder Teixeira Melo
12:45 – 13:00	Discussion
16:30 – 17:45	Conferences – Auditório 1 – Térreo		Sandra Regina Loggetto e Luiz de Melo Amorim Filho
16:30 – 17:00	Massive transfusion protocols in pediatrics		Steven R. Sloan
17:00 – 17:30	Age of Transfused Red blood cells		Steven R. Sloan
17:30 – 17:45	Discussion
16:30 – 17:45	Conferences – Auditório 3 – Térreo		José Roberto Luzzi e Afonso José Pereira Cortez
16:30 – 17:00	Transfusion medicine in the age of genomics		Connie Westhoff
17:00 – 17:30	Hemostatic and metabolic changes in therapeutic apheresis		Marisa Marques
17:30 – 17:45	Discussion
16:30 – 18:00	Best Scientific Works Presentation – Hemotherapy and Cell Therapy – Salas 14 / 15 – Andar Superior		José Francisco Comenalli Marques Jr. e Helio Moraes de Souza
16:30 – 16:40	INFLUÊNCIA DO PLASMA DE PACIENTES COM DOENÇA DO ENXERTO CONTRA O HOSPEDEIRO SOBRE O POTENCIAL IMUNOSSUPRESSIVO DAS CÉLULAS TRONCO MESENQUIMAIS		Carvalho AES, Serejo TRT, Alborguetti MR, Schivianato J, Simoes BP, Bettarello G, Araujo FS ( Autores )
16:40 – 16:50	Odds of being HIV positive among Male Blood Donors in Four Large Brazilian Blood Centers		Salomon T, Ozahata MC, Custer B, Gomes IC, Oliveira CDL, Duarte ME, Loureiro P, Carneiro-Proietti ABF, Sabino EC, Almeida-Neto C ( Autores )
16:50 – 17:00	NK cells engineered with a Chimeric Antigen Receptor Targeting CD19		Silvestre RN, Mizukami A, Pereira MSF, Fantacini DMC, Vaz LD, Moco PD, Farias KCRM, Antonietto KS, Covas DT, Castro VP ( Autores )
17:00 – 17:10	PRODUÇÃO E RESPOSTA DE LINFÓCITOS T CD8+ POR ESTÍMULO DE CÉLULAS DENDRÍTICAS FUSIONADAS COM PLASMÓCITOS DO MIELOMA MÚLTIPLO E DA IL-15		Barbosa MES, Lima TS, Machado BL, Maiolino A, Rossi MID, Jesus EFO, Nogueira CM, Magalhães R, Porto LC, Dutra HDS ( Autores )
17:10 – 17:20	Production and characterization of monoclonal antibody with specific recognition of human mesenchymal stem cell antigens (IL1-ra).		Inácio JC, Deffune E, Neto FVO ( Autores )
17:20 – 17:30	Patient Blood Management (PBM) guiado por tromboelastograma e seu impacto no consumo de componentes sanguíneos alogénicos		Deveza MM, Galvão M, Beleza A ( Autores )
17:30 – 17:40	Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: the development of a national platform.		Picanco-Castro V, Moco P, Mizukami A, Vaz LD, Pereira M, Bomfim A, Antonietto KS, Farias KCRM, Covas DT ( Autores )
17:40 – 17:50	Propriedades Funcionais das Variantes Hb S e Hb C em Bolsas de sangue – Um Estudo Prospetivo da Função versus Tempo de Armazenamento		Jorge SE, Grigoleto MRP, Castro MLB, Costa FF, Sonati MF ( Autores )
17:50 – 18:00	Efeito da Suplementação de L-arginina sobre o eritrograma de ratas Wistar submetidas à quimioterapia com 5-Fluorouracil		Fagiani MAB, Tsujigushi LK, Reis LSLS, Mello FA, Yabuki D, Gonalves GV, Fluminhan A, Laposy CB, Goiozo PFI, Giuffrida R ( Autores )

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-Table: Regulation		Vanderson Rocha e João Batista da Silva Jr.
08:30 – 08:55	Regulation of Adavanced Therapies in the USA	Mauro Avanzi
08:55 – 09:20	Legislation in Cell Therapy in Brazil	Ana Paula Rocha Diniz Zanelli
09:20 – 09:45	Producing Car-T in Brazil : Is it Feasible	Vanderson Rocha
09:45 – 10:00	Discussion

Time	Subject	Speaker	Moderator
08:30 – 10:00	Hodgkin Lymphoma ( Auditório 5 – Térreo )		Otávio Baiocchi e Samir Kanaan Nabhan
08:30 – 08:50	How do I treat Nodular lymphocyte predominant Hodgkin lymphoma ?	Adriana Penna
08:50 – 09:10	Tumor microenvironment in classic Hodgkin's lymphoma	Fernando Soares
09:10 – 09:30	Transplantation in classic Hodgkin's lymphoma	Fábio Kerbauy
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Níveis de Hemoglobina, Albumina e DHL são fatores preditores de óbito em pacientes com Linfoma de Hodgkin infanto-juvenil	Azevedo EF, Tenório TBS, Almeida RDS, Pedrosa F, Lucena-Silva N ( Autores )
09:40 – 09:50	Detecção de células de Reed-Sternberg por citometria de fluxo e seu papel no auxílio ao diagnóstico de linfoma de Hodgkin.	Cardoso CC, Santos-Pirath IM, I-Ching L, Lange BG, Silva JP, Koide GB, Ribeiro AAB, Pereira CHJ, Del-Moral JAG, Santos-Silva MC
09:50 – 10:00	Discussion
08:30 – 10:00	Hematopoietic Stem Cell Transplantation (HSCT). What should the hematologist know? ( Auditório 6 – Térreo )		Ricardo Pasquini e Nelson Hamershlak
08:30 – 08:50	In which clinical situations should you indicate or contraindicate a HSCT nowadays	Belinda Pinto Simões
08:50 – 09:10	Graft vs. Host Disease. New therapeutic approaches for the safety of HSCT	Afonso Celso Vigorito
09:10 – 09:30	Cell therapy as a complement or replacement for HSCT	Nelson Hamerschlak
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	QUALIDADE DE VIDA EM PACIENTES COM DOENÇA FALCIFORME SUBMETIDOS AO TRANSPLANTE DE CÉLULAS-TRONCO HEMATOPOÉTICAS: UM ESTUDO LONGITUDINAL	Lotério LDS, Oliveira-Cardoso EA, Mareze JTG, Guimarães ALC, Santos MAD, Simões BP ( Autores )
09:40 – 09:50	Colonização por Bactérias Gram-Negativas (GN) produtoras de carbapenemase (ERC) – importância no risco de bacteremia e óbito em pacientes submetidos a transplante de células tronco-hematopoiéticas (TMO)	Bellizze MA, Jesus PGA, Akamine FM, Marcal AJ, Santos RMCD, Gomes RRC, Rangel LC, Rejane M, Garnica M ( Autores )
09:50 – 10:00	Discussion
11:30 – 13:00	Treatment of Multiple Myeloma – How Do I Treat It? ( Auditório 5 – Térreo )		Glaciano Nogueira Ribeiro e Jorge Vaz Pinto Neto
11:30 – 11:50	Patients Eligible for Transplantation	Ângelo Maiolino
11:50 – 12:10	Ineligible Patients for transplantation	Vânia Tietsche de Moraes Hungria
12:10 – 12:30	Relapsed Patients	Edvan de Queiroz Crusoé
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:50	Stew in its own juice: Protein homeostasis machinery inhibition reduces cell viability in multiple myeloma cell lines	Oliveira MB, Sanson LFG, Eugênio AIP, Colleoni GWB ( Autores )
12:30 – 12:50	PERFIL GENÔMICO DE CÉLULAS-TRONCO DE MEDULA ÓSSEA EM PORTADORES DE MIELOMA MÚLTIPLO: IDENTIFICAÇÃO DE POTENCIAIS VIAS ASSOCIADAS A SOBREVIDA E ÓBITO	Takakura ET, Martins LNGF, Binato R, Abdelhay ESFW, Barbosa DS, Panis C ( Autores )
12:50 – 13:00	Discussion
11:30 – 13:00	Chronic Lymphoproliferative Disorders ( Auditório 6 – Térreo )		Mihoko Yamamoto e Vera Lúcia Figueiredo
11:30 – 11:50	Update on diagnosis and prognostic factors in CLL	Matheus Vescovi Gonçalves
11:50 – 12:10	Update on the treatment of CLL	Celso Arrais
12:10 – 12:30	Infections in CLL patients in the current treatment setting	Márcio Nucci
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:50	Chronic lymphocytic leukemia (CLL): protein kinase akt and microRNAs gene expression evaluation and their importance in disease pathogenesis	Gomes LC, Araújo SSS, Resende RR, Parreira RC, Ferreira CN, Duarte RCF, Favretto F, Ferreira MCE, Carvalho MDG, Sabino AP ( Autores )
12:30 – 12:50	Desfechos a longo prazo e fatores associados à resposta completa em pacientes com Leucemia de Células Pilosas: 30 anos de experiência de um único centro	Takakura ET, Martins LNGF, Binato R, Abdelhay ESFW, Barbosa DS, Panis C ( Autores )
12:50 – 13:00	Discussion
11:30 – 13:00	PNH ( Salas 1, 2 e 3 – Andar Superior )		Rodrigo Calado e Phillip Scheinberg
11:30 – 11:50	Treatment of Treatment of Aplastic Anemia With HPN Clone	Carlos Bernardo Loureiro Lima
11:50 – 12:10	The Way Forward: Targeting Intravascular and Extravascular Haemolysis at the level of C3	Antonio Risitano
12:10 – 12:30	Transplant Indications for HPN	Gérard Socié
12:30 – 12:50	Scientific Works – Oral Presentations
12:50 – 13:00	Discussion
16:30 – 17:45	Conferences ( Auditório 5 – Térreo )		Marcia Garnica e Vânia Tietsche de Moraes Hungria
16:30 – 17:00	Infection in the "mibs" and "mabs" era: what's popping up?	Márcio Nucci
17:00 – 17:30	Multiple Myeloma Imaging Tests	Alípio Gomes Ormond Filho
17:30 – 17:45	Discussion
16:30 – 17:45	Conferences ( Auditório 6 – Térreo )		Vanderson Rocha e Luiz Gonzaga Tone
16:30 – 17:00	The prototype of success: from understanding to treatment	André Neder Ramires Abdo
17:00 – 17:30	Treating Adults like Children – Pediatric Protocols in Adults with ALL	Dan Douer
17:30 – 17:45	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Acute lymphoblastic leukemia: Evolution or Revolution? – (Salas 7/8 – Mezanino)		Mariana Michalowski e Rosana Cipolotti
08:30 – 08:50	Risk assessment: changes in concept?	Raul Ribeiro
08:50 – 09:10	New subtypes of pediatric ALL: fact or myth?	Carlos Alberto Scrideli
09:10 – 09:30	What has changed in the treatment?	Daniel Freigeiro
09:30 – 09:40	Scientific Works – Oral Presentations
09:30 – 09:40	Prognostic Value of Bone Marrow Endothelial Cells on Disease-Free Survival of Children with B-cell Precursor Acute Lymphoblastic Leukemia	Oliveira E, Land MGP, Teixeira LA, Ferrão PM, Bacellar TS, Dumas ML, Orfao A, Costa ES ( Autores )
09:40 – 09:50	Aumento da expressão das isoformas Ik6 e Ik10 do gene IKZF1 ao diagnóstico e seu impacto no prognóstico da leucemia linfoide aguda da infância	Moreira LBP, Queiroz R, Perna E, Suazo VK, Tone LG, Scrideli CA ( Autores )
09:40 – 10:00	Discussion
08:30 – 10:00	Advances in diagnosis and Treatment (Salas 10/11 – Mezanino)		Josefina Aparecida Pellegrini Braga e Andrea Angel
08:30 – 08:50	When to indicate therapeutic apheresis	Antonio Sérgio Torloni
08:50 – 09:10	How to interpret negative direct coombs in autoimmune hemolytic anemia	Shirley Castilho
09:10 – 09:30	Frequency of red cell genotyping in patients with thalassemia major	Lílian Castilho
09:30 – 09:40	Scientific Works – Oral Presentations
09:30 – 09:40	Evaluating prevalence and risk factors for albuminuria in a cohort of 471 pediatric patients with sickle cell anemia from the state of Minas Gerais	Belisário AR, Almeida JA, Vieira ELM, Mendes FG, Miranda AS, Planes W, Silva DM, Rezende PDV, Viana MB, Silva ACSE ( Autores )
09:40 – 09:50	Baixa densidade mineral óssea de crianças e adolescentes com doença falciforme – estamos diagnosticando?	Chaves CES, Angel A, Siviero-Miachon AA, Spínola-Castro AM, Braga JAP ( Autores )
09:50 – 10:00	Discussion
11:30 – 13:00	B cell Non-Hodgkin lymphoma in pediatrics : new paths? (Salas 7/8 – Mezanino)		Claúdio Galvão de Castro Jr. e Gustavo Ribeiro Neves
11:30 – 11:50	Novel therapies in B cell Non-Hodgkin lymphoma: where are we and prospects	Renato Melaragno
11:50 – 12:10	Refractory B cell Non-Hodgkin lymphoma: what do we have at present?	Ana Rosa Braz
12:10 – 12:30	B cell Non-Hodgkin lymphoma x bone marrow transplantation: autologous or haploidentical?	Adriana Seber
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:40	Leucemia promielocítica aguda recaída na infância: comparação entre tratamento com transplante autólogo e alogênico	Lira LAS, Dutra MP, Cristofani LM ( Autores )
12:40 – 12:50	ESTUDO EPIDEMIOLÓGICO DAS LEUCEMIAS LINFOIDES AGUDAS COM BASE NA EXPOSIÇÃO AMBIENTAL E HÁBITOS DURANTE A GESTAÇÃO	Murra GRC, Martins BP, Salvador GB, Faria TMV, Oliveira MA, Baglioli BF, Lopes LF ( Autores )
12:50 – 13:00	Discussion
11:30 – 13:00	Hemoglobinopatias – novas abordagens (Salas 10/11 – Mezanino)		Márcia Lima Verde Campos de Oliveira e Marcos Borato Viana
11:30 – 11:50	Contracepção nas mulheres com doença falciforme	Cristina Guazzelli
11:50 – 12:10	Estado da arte no manejo da dor na DF	Jane Hankins
12:10 – 12:30	Agonistas da hepcidina como ferramentas terapêuticas	Stefano Rivella
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:40	Sickle cell/beta-thalassemia: identification of beta-thalassemia mutations, beta globin gene cluster haplotypes and co-inheritance of alpha-thalassemia	Oliveira EL, Silva NP, Belisário AR, Viana MB ( Autores )
12:40 – 12:50	AVALIAÇÃO NEUROCOGNITIVA E DA HEMODINÂMICA ENCEFÁLICA DE CRIANÇAS E ADOLESCENTES COM DOENÇA FALCIFORME	Souza AMA, Junior FMP, Carvalho AEV, Cruz TT, Silva BME ( Autores )
12:50 – 13:00	Discussion
16:30 – 17:45	Conferences (Salas 7/8 – Mezanino)		Denise Bousfield da Silva e Israel Bendit
16:30 – 17:00	Next-generation sequencing for minimal residual disease in B-ALL	Paulo V. Campregher
17:00 – 17:30	Clinical experience with next generation sequencing in pediatric leukemia	Raul Ribeiro
17:30 – 17:45	Discussion
16:30 – 17:45	Advances in pediatric hematology and hemotherapy (Salas 10/11 – Mezanino)		Célia Martins Campanaro e Ana Cláudia dos Anjos
16:30 – 17:00	Inflammatory bowel disease and iron deficiency anemia not responsive to oral treatment – how do I treat it?	Vera Lucia Sdepanian
17:00 – 17:30	Treatment of vasculopathy in CNS in sickle cell disease	Jane Hankins
17:30 – 17:45	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Hematological complications of yellow fever ( Auditório 2 – Hall E / Térreo )		Paula Ribeiro Villaça e Bianca Stefanello
08:30 – 08:50	Clinical spectrum of Yellow Fever	Ho Yeh Li
08:50 – 09:10	Coagulopathy of Yellow Fever and local experience 1 (UFMG)	Suely Meireles Rezende
09:10 – 09:30	Local experience 2 (USP)	Paula Ribeiro Villaça
09:20 – 09:30	Local experience 3 (Unicamp)	Fabrício Biscaro Pereira
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	Characterization of the glycosylation profile of a new recombinant factor VIII produced in Sk-Hep human cell line	Fantacini DMC, Carillo S, Butler M, Neto MSA, Covas DT, Picanco-Castro V ( Autores )
09:40 – 09:50	Papel da Troca plasmática na insuficiência hepática aguda pós infecção pelo vírus da febre amarela. Descrição da experiência de um serviço quaternário.	Melo RCB, Li HY, Tatsui NH, Nakamura MM, Inowe EK, Carvalho HB, Okazaki E, Villaca PR, Rocha V, Nukui Y ( Autores )
09:50 – 10:00	Discussion
11:30 – 13:00	Round-table: Inherited bleeding disorders ( Auditório 2 – Hall E / Térreo )		Margareth Castro Ozelo e Ana Clara Kneese Virgílio do Nascimento
11:30 – 11:50	Inhibitor development and management in hemophilia: an update	Marijke van den Berg
11:50 – 12:10	How to manage comorbidities in VWD and hemophilia?	Alessandra Prezotti
12:10 – 12:30	Hemostasis in Liver Disease	Bianca Stefanello
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:40	Immune tolerance induction in patients with hemophilia A and inhibitors: preliminary results of the Brazilian Immune Tolerance (BrazIT) Study	Camelo RM, Magalhães LP, Jardim LL, Zuccherato LW, Oliveira AG, Franco VKB, Tan DM, Roberti MDRF, Chaves DG, Rezende SM ( Autores )
12:40 – 12:50	Persistence of anti-FVIII IgG4 and CD4+ IL-21+ and absence of CD19+ IL-10+ may be used as a marker of a poor prognosis in immune tolerance induction (ITI) treatment for hemophilia A patients with inhibitor	Delima-Montalvão SA, Sambo AL, Hosokawa M, Della-Piazza M, Foschi N, Costa-Lima C, Yamaguti-Hayakawa G, Medina SS, Ozelo MC ( Autores )
12:50 – 13:00	Discussion
16:30 – 17:45	Conferences ( Auditório 2 – Hall E / Térreo )		Ana Clara Kneese Virgílio do Nascimento e Dayse Maria Lourenço
16:30 – 17:00	Patent foramen ovale and criptogenic stroke – Guilty	Erich Vinicius de Paula
16:30 – 17:00	Patent foramen ovale and criptogenic stroke – Inocent	Ana Clara Kneese Virgílio do Nascimento
17:00 – 17:30	Controversies in oral anticoagulation – When warfarin is the best option	Daniel Dias Ribeiro
17:00 – 17:30	Controversies in oral anticoagulation – When DOACs are the best option	Dayse Maria Lourenço
17:30 – 17:45	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-table: Diagnostic Advances ( Auditório 4 – Hall E / Térreo )		Adriano Morita da Silva e Paulo Augusto Silveira
08:30 – 08:50	Idiopathic cytopenias	Sara Teresinha Olalla Saad
08:50 – 09:10	Primary Hemochromatosis	Sandra Fátima Menosi Gualandro
09:10 – 09:30	Congenital bone marrow failure	Rodrigo Calado
09:30 – 09:50	Scientific Works – Oral Presentations
09:30 – 09:40	MUTAÇÕES EM ACERULOPLASMINEMIA REVELAM DIFERENÇAS TECIDO-ESPECÍFICAS NA EXPRESSÃO DE FERROPORTINA E ISOFORMAS DE CERULOPLASMINA	Borges MD, Campioni MDP, Albuquerque DM, Lanaro C, Costa FF, Fertrin KY ( Autores )
09:40 – 09:50	Predictors of Red Blood Cell Alloimmunization in a Brazilian Sickle Cell Disease Cohort	Kelly S, Cruz DTS, Dinardo C, Valgueiro MDC, Cayres L, Castilho SL, Guo Y, Sabino E, Page G, Flor-Park MV, Carneiro-Proietti ABF, Rodrigues DO, Mota RA, Maximo C, Loureiro P, Custer B ( Autores )
09:50 – 10:00	Discussion
11:30 – 13:00	Round-table: Sickle cell disease ( Auditório 4 – Hall E / Térreo )		Sandra Fátima Menosi Gualandro e Paula de Melo Campos
11:30 – 11:50	Importance of inflammation markers in the pathophysiology of sickle cell disease	Nicola Conran
11:50 – 12:10	Mortality in patients from Rio de Janeiro	Clarisse Lopes de Castro Lobo
12:10 – 12:30	Alterações neurológicas em adultos	Daniela Laranja
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:40	ENVOLVIMENTO DE SUBTIPOS DE MONÓCITOS E CITOCINAS INFLAMATÓRIAS NA FISIOPATOLOGIA DA ANEMIA FALCIFORME	Junior ALS, Garcia NP, Santos APCD, Soares GAS, Costa TCC, Costa AG, Filho OAM, Paula EV, Marie AMA ( Autores )
12:40 – 12:50	Heme e hemopexina são carreados por diferentes lipoproteínas circulantes em pacientes com anemia falciforme	Vendrame F, Olops L, Saad STO, Costa FF, Fertrin KY ( Autores )
12:50 – 13:00	Discussion
16:30 – 17:45	Conferences: Hereditary Anemias ( Auditório 4 – Hall E / Térreo )		Sara Teresinha Olalla Saad e Fernando Ferreira Costa
16:30 – 17:00	Advances in differential diagnosis of congenital hemolytic anemias	Roberta Russo
17:00 – 17:30	Gene therapy for hemoglobinopathies	Stefano Rivella
17:30 – 17:45	Discussion

Time	Subject	Speaker	Moderators
11:30 – 13:00	Round-table: Clinical significance of the investigation of minimal residual disease by flow cytometry (12/13 Piso Superior)		Elizabeth Xisto Souto e Vergílio Colturato
11:30 – 11:50	MRD in B-cell Acute Lymphoblastic Leukemia	Elaine Sobral
11:50 – 12:10	MRD in Multiple Myeloma	Maura Ikoma
12:10 – 12:30	MRD in CLL	Gislaine Borba Oliveira
12:30 – 12:50	Scientific Works – Oral Presentations
12:30 – 12:40	PESQUISA DE DOENÇA RESIDUAL MÍNIMA POR CITOMETRIA DE FLUXO MULTIPARAMÉTRICA DE NOVA GERAÇÃO (NGF) EM PACIENTES COM MIELOMA MÚLTIPLO APÓS O TRANSPLANTE AUTÓLOGO DE CÉLULAS-TRONCO HEMATOPOIÉTICAS	Salgado ABS, Pontes RM, Pimenta G, Dutra HS, Magalhães RJP, Costa ES, Maiolino A ( Autores )
12:40 – 12:50	IMPORTÂNCIA DA CITOMETRIA DE FLUXO MULTIPARAMÉTRICA NO DIAGNÓSTICO E ACOMPANHAMENTO DE LINFOMA ANAPLÁSICO DE GRANDES CÉLULAS ALK+ NA FORMA LEUCEMIZADA	Riscarolli EB, Canellas MC, Facio C, Marthins PH, Sutter D, Breder L, Land MGP, Milito C, Costa ES ( Autores )
12:50 – 13:00	Discussion
16:30 – 17:45	Collaborative conference GBCFLUX / Laboratory Hematology – Pancytopenias (12/13 Piso Superior)		Maria Claudia Santos da Silva e Elizabeth Xisto Souto
16:30 – 17:00	Differential diagnoses	Lígia Niero Melo
17:00 – 17:30	Role of flow cytometry in the evaluation of pancytopenias	Irene Lorand-Metze
17:30 – 17:45	Discussion

Time	Subject	Speaker	Moderators
08:30 – 10:00	Round-table: Hematologic manifestations of infectious agents		Cristina Bortolheiro e Kleber Fertrin
08:30 – 08:50	HIV-induced hematologic disorders	Lígia Niero Melo
08:50 – 09:10	Reactive lymphocytosis	Kleber Fertrin
09:10 – 09:30	H. pylori-associated hematologic disorders	Lígia Niero Melo
09:30 – 09:40	Scientific Works – Oral Presentations
09:50 – 10:00	Discussion
16:30 – 17:45	Collaborative conference GBCFLUX / Laboratory Hematology – Pancytopenias		Maria Claudia Santos da Silva e à definir
16:30 – 17:00	Differential diagnoses	Lígia Niero Melo
17:00 – 17:30	Role of flow cytometry in the evaluation of pancytopenias	Irene Lorand-Metze
17:30 – 17:45	Discussion

Time	Subject	Speakers	Moderator
08:30 – 18:00	14th Symposium on Hospital Psychology in Hematology – sala 4/5 – Andar Superior		Heloisa Benevides de Carvalho Chiattone e Regina Célia Rocha ( Coordinators )
08:30 – 09:30	Conference: HOSPITAL PSYCHOLOGY – 64 YEARS OF A GREAT JOURNEY IN PSYCHOLOGY	Mathilde Neder	Heloisa Benevides de Carvalho Chiattone
09:30 – 10:45	Round-table: BUILDING THE CARE		Eliana de Souza Teixeira
09:30 – 10:00	THE DNA PROGRAM – DEVELOPING OUR ATTITUDES	Renato Ferreira Pereira e Ana Bizzotto Melo
10:00 – 10:30	CHANGING CONCEPTS – Insertion of the oncology culture in the multi team in a Maternity Hospital of São Paulo	Flávia R. Pereira
10:30 – 11:00	HOW HAVE WE WORKED CARE FOR THE EMPLOYEES	Heloisa Benevides de Carvalho Chiattone e Ricardo Sato
11:00 – 11:15	Discussion
11:15 – 12:15	Round-table: PATIENT EXPERIENCE AS ESSENCE OF CARE		Márcia Aparecida de Oliveira
11:15 – 11:45	Patient Experience as a model of care at Hospital Samaritano – SP	Camila Cristina Pires Nascimento
11:45 – 12:15	The Development Project of the Patient Experience Group of Carlos Chagas Hospital – Guarulhos	Carlos Eduardo Cardoso
12:15 – 12:30	Discussion
12:30 – 14:45	Pause for Lunch
14:45 – 15:15	Mini-Conference: ONCO-HEMATO-TRANSPLANTATION – THE INTERDISCIPLINARY WAY	Maribel Pelaez Doro	Leticia Aparecida da Silva Marques
15:15 – 15:30	Discussion
15:30 – 16:00	Mini-Conference: LIVING AFTER CANCER … WHICH WAY SHOULD I FOLLOW?	Érika Arantes de Oliveira Cardoso	Priscila Mendes Paiva
16:00 – 16:15	Discussion
16:15 – 16:45	Mini-Conference: ORGANIZATION OF THE PSYCHOLOGY SERVICE IN ONCOLOGICAL HOSPITAL – ICESP – SP	Lórgio Henrique Diaz Rodriguez	Regina Célia Rocha
16:45 – 18:00	Oral Presentations: Creating and Recreating Actions for Better Patient Care		Heloisa Benevides de Carvalho Chiattone
16:45 – 17:00	O DESPERTAR DO ESTUDANTE DE MEDICINA PARA AS MÁS NOTÍCIAS: ENSINANDO A HUMANIZAR ATRAVÉS DA HEMATOLOGIA	Botelho LFB, Gomes BN, Brito AS, Frana KAN, Fernandes AS, Abrantes MBSO, Silva ICB, Medeiros FMT ( Autores )
17:00 – 17:15	Percepção de barreiras e facilidades no trabalho em equipe multiprofissional em uma unidade de Transplante de Células-Tronco Hematopoéticas	Silva AK, Lotério LDS, Mareze JTG, Guimarães ALC, Simões BP, Santos MAD, Oliveira-Cardoso EA ( Autores )
17:15 – 17:30	Os desafios da intervenção psicológica em grupos de cuidadores de pacientes portadores de Doença Falciforme	Silva SA, Faria NMSA, Perina EM ( Autores )
17:30 – 18:00	FANTASTIC MARVELS AND JEDIS: O USO DOS VINGADORES PARA TORNAR O ENSINO DA HEMOSTASIA DIVERTIDO	Fernandes AS, Brito AS, Botelho LFB, Gomes BN, Abrantes MBSO, Frana KAN, Silva ICB, Medeiros FMT ( Autores )
18:00	Encerramento

Time	Subject	Speakers	Moderator
08:30 – 12:30	8th Advocacy Forum to improve access to hematological treatments – Sala 6 – Andar Superior		Melissa A. Pereira(coordinator)
08:30 – 09:00	Opening Oficial	Flávio Francisco Vormittag, Eduardo Magalhães Rego, Eduardo Fróes e Tânia Maria Onzi Pietrobelli
09:00 – 10:00	1st panel – National policies to ensure access to quality and safety of treatments: a right or a privilege	Flávio Francisco Vormittag, Tânia Maria Onzi Pietrobelli e Maria Zeno Soares da Silva	Luah Galvão
09:00 – 10:00	Patient care: unmet needs
09:00 – 10:00	Improving the health quality – Networks and accreditation
09:00 – 10:00	Overcoming obstacles in thalassemia, hemophilia and sickle cell disease: Improving patient adherence
10:00 – 10:30	Discussion
10:30 – 11:30	2nd panel – How is the Treatment of Thalassemia in Brazil? Collaboration, essential condition for improvement of treatments	Monica Verissimo, Juliano Lara, Giorgio Baldanzi e Gabriela Olivatto	Luah Galvão
10:30 – 11:30	Iron chelation: how to adapt the needs of each patient
10:30 – 11:30	Role of magnetic resonance imaging for evaluation of iron overload
10:30 – 11:30	Adjusting the treatment according to the patient's profile and need: less iron, longer life
10:30 – 11:30	Treatment adherence: a patient's perspective
11:30 – 12:00	Questions and Answers
12:30	Closing

Time	Subject	Speaker	Moderators
14:00 – 18:00	1st Symposium on Biomedical Sciences (Salas 1/2/3 – Mezanino)		Maria de Fátima Sonati e Helio Moraes de Souza (coordenators)
14:00 – 14:40	Quality control in the hematology laboratory	Claudio Ernesto Albers Mendes
14:40 – 15:20	Gene editing in hematology	Maria de Fátima Sonati
15:20 – 16:00	Difficult diagnoses in hemoglobinopathies	André Rolin Belisário
16:00 – 16:30	Break
16:30 – 17:10	Anemias differential diagnosis	Maria Stella Figueiredo
17:10 – 17:50	Laboratory diagnosis of acute leukosis: cytology, flow cytometry and cytogenetics	Maria de Lourdes Chauffaille

Time	Subject	Speaker	Moderator
10:15 – 11:15	Myeloproliferative Neoplasms – from Pathogenesis to Personalized Predictions ( Auditório 5 e 6 -Hall E / Térreo )	Tony Green	Eduardo Magalhães Rego e Renato Sampaio Tavares

Time	Subject	Speaker	Moderator
13:15 – 14:45	BAYER – Challenges and future perspectives in the VTE treatment		Dayse Maria Lourenço
13:15 – 13:35	Current recommendations on the treatment of venous thromboembolism: available data and unmet needs in patients with cancer	Élbio Antonio D'Amico
13:35 – 13:55	VTE extended therapy: in which patients and how long?	Jan-Beyer Westendorf
13:55 – 14:15	VTE treatment duration: clinical cases discussion	Jan-Beyer Westendorf
14:15 – 14:45	Discussion and closing	Dayse Maria Lourenço
13:15 – 14:45	CELGENE: OPTIMIZING LOW RISK MYELODYSPLASIC SYNDROME TREATMENT
13:15 – 13:20	Introduction	Silvia M. M. Magalhães
13:20 – 13:45	What I should know before starting treatment for patients with MDS	Elvira Velloso
13:45 – 14:20	Benefits and management of lenalidomide in MDS	Silvia M. M. Magalhães
14:20 – 14:45	Questions & Answers
	BRISTOL: Changes in MM Treatment – Sala 7/8 – Andar Superior
13:15 – 13:25	Opening	Vânia Tietsche de Moraes Hungria
13:35 – 13:40	What to consider before deciding the treatment under relapse	Angelo Maiolino
13:40 – 14:10	RRMM: the option for each patient	Ajai Chari
14:10 – 14:30	Further Steps in the Treatment of RRMM-New Combinations	Ajai Chari
14:30 – 14:45	Questions & Answers	all
13:15 – 14:45	DELBONI: Everything you Always want to know about minimal residual disease (MRD) in acute leukemia – Auditório 1 – Térreo		Belinda Pinto Simões e Monika Conchon ( Chairs )
13:15 – 13:20	Introduction	Belinda Pinto Simões
13:20 – 13:55	MRD in LLA	Oliver Ottmann
13:55 – 14:30	MRD in AML	Eduardo Magalhães Rego
14:30 – 14:45	Discussion
13:15 – 14:45	FLEURY – Auditório 3 – Térreo	Alex Freire Sandes, Aline dos Santos Borgo Perazzio, Christiane Pereira Gouvea, Flávia Zacchi, Jussara Castelli, Marçal A. da Silva, Maria de Lourdes Chauffaille e Matheus Vescovi Gonçalves
	Bench-To-Bedside: The Individualized Hematology. Diagnostic Aspects of Oncohematological Diseases in the Age of New Generation Sequencing
	D-dimer elevation: What to consider besides thrombosis and how they can be interpreted
13:15 – 14:45	BIOMARIN: Concepts and advances of gene therapy with AAV in the treatment of hemophilia – Salas 10 / 11 – Andar Superior	Valder Arruda e Margareth Castro Ozelo